https://lakefrontbio.com/press-releases/galapagos-discontinues-phase-ii-trial-for-glpg0259-focuses-resources-on-other-rheumatoid-arthritis-programs/ 2023-12-10T21:51:37+00:00 https://lakefrontbio.com/press-releases/galapagos-stopt-fase-ii-studie-met-glpg0259-en-richt-zich-op-haar-andere-reuma-programmas/ 2023-12-10T21:51:37+00:00 https://lakefrontbio.com/press-releases/dr-vicki-sato-to-be-appointed-to-galapagos-board-of-directors/ 2023-12-10T21:51:37+00:00 https://lakefrontbio.com/press-releases/dr-vicki-sato-voorgedragen-voor-raad-van-bestuur-van-galapagos/ 2023-12-10T21:51:38+00:00 https://lakefrontbio.com/press-releases/galapagos-increases-share-capital-through-warrant-exercises-32/ 2023-12-10T21:51:38+00:00 https://lakefrontbio.com/press-releases/galapagos-verhoogt-aandelenkapitaal-door-uitoefenen-van-warrants-5/ 2023-12-10T21:51:38+00:00 https://lakefrontbio.com/press-releases/galapagos-starts-phase-ib-clinical-study-in-cancer-patients/ 2023-12-10T21:51:38+00:00 https://lakefrontbio.com/press-releases/galapagos-start-fase-ib-klinische-studie-bij-kankerpatienten/ 2023-12-10T21:51:38+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-record-revenues-and-increased-profitability-in-2010/ 2023-12-10T21:51:39+00:00 https://lakefrontbio.com/press-releases/galapagos-behaalt-recordomzet-en-vergroot-winstgevendheid-in-2010/ 2023-12-10T21:51:39+00:00 https://lakefrontbio.com/press-releases/galapagos-delivers-candidate-drug-in-gsk-alliance-receives-e6-7-million/ 2023-12-10T21:51:39+00:00 https://lakefrontbio.com/press-releases/galapagos-levert-kandidaat-medicijn-in-gsk-alliantie-ontvangt-e67-miljoen/ 2023-12-10T21:51:39+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-e4-million-in-milestones-from-servier/ 2023-12-10T21:51:40+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-succesbetaling-van-e4-miljoen-van-servier/ 2023-12-10T21:51:40+00:00 https://lakefrontbio.com/press-releases/galapagos-creates-new-warrant-plan-10/ 2023-12-10T21:51:40+00:00 https://lakefrontbio.com/press-releases/galapagos-creeert-nieuw-warrantplan-11/ 2023-12-10T21:51:41+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-e2-7-million-grant-for-antiviral-drug-discovery/ 2023-12-10T21:51:41+00:00 https://lakefrontbio.com/press-releases/galapagos-krijgt-e27-miljoen-subsidie-voor-antivirale-medicijnontwikkeling/ 2023-12-10T21:51:41+00:00 https://lakefrontbio.com/press-releases/galapagos-and-merck-co-inc-agree-to-end-strategic-alliances/ 2023-12-10T21:51:42+00:00 https://lakefrontbio.com/press-releases/galapagos-en-merck-co-komen-overeen-allianties-te-beeindigen/ 2023-12-10T21:51:42+00:00 https://lakefrontbio.com/press-releases/galapagos-achieves-e137-million-revenues-in-2010-outlook-for-continued-strong-2011-performance/ 2023-12-10T21:51:42+00:00 https://lakefrontbio.com/press-releases/galapagos-behaalt-omzet-van-e137-miljoen-in-2010-verwacht-sterk-2011/ 2023-12-10T21:51:42+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-e7-4-m-milestone-in-arthritis-alliance-with-glaxosmithkline/ 2023-12-10T21:51:42+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-succesbetaling-van-e74-miljoen-in-artritis-alliantie-met-glaxosmithkline/ 2023-12-10T21:51:43+00:00 https://lakefrontbio.com/press-releases/galapagos-affiliate-biofocus-extends-collaboration-with-amgen-into-2012/ 2023-12-10T21:51:43+00:00 https://lakefrontbio.com/press-releases/galapagos-en-amgen-breiden-samenwerking-uit-tot-in-2012/ 2023-12-10T21:51:43+00:00 https://lakefrontbio.com/press-releases/galapagos-achieves-milestones-broadens-scope-of-roche-alliance/ 2023-12-10T21:51:43+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-e35-miljoen-aan-succesbetalingen-en-breidt-alliantie-met-roche-uit/ 2023-12-10T21:51:44+00:00 https://lakefrontbio.com/press-releases/galapagos-increases-share-capital-through-warrant-exercises-33/ 2023-12-10T21:51:44+00:00 https://lakefrontbio.com/press-releases/galapagos-verhoogt-aandelenkapitaal-door-uitoefenen-van-warrants-6/ 2023-12-10T21:51:44+00:00 https://lakefrontbio.com/press-releases/galapagos-candidate-cachexia-drug-glpg0492-shows-good-safety-and-profile-suitable-for-once-daily-oral-dosing/ 2023-12-10T21:51:45+00:00 https://lakefrontbio.com/press-releases/galapagos-kandidaat-medicijn-voor-cachexia-glpg0492-laat-goed-veiligheidsprofiel-zien/ 2023-12-10T21:51:45+00:00 https://lakefrontbio.com/press-releases/galapagos-business-update-11/ 2023-12-10T21:51:45+00:00 https://lakefrontbio.com/press-releases/galapagos-business-update-12/ 2023-12-10T21:51:45+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-transparency-notification-3/ 2023-12-10T21:51:46+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-kennisgeving-van-belangrijke-deelneming-3/ 2023-12-10T21:51:46+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-e3-7-million-grant-for-cystic-fibrosis-program/ 2023-12-10T21:51:46+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-e37-miljoen-subsidie-voor-taaislijmziekte-programma/ 2023-12-10T21:51:47+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-transparency-notifications-3/ 2023-12-10T21:51:47+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-kennisgevingen-van-belangrijke-deelneming-2/ 2023-12-10T21:51:47+00:00 https://lakefrontbio.com/press-releases/galapagos-completes-private-placement-by-issuance-of-2389347-new-ordinary-shares/ 2023-12-10T21:51:47+00:00 https://lakefrontbio.com/press-releases/galapagos-rondt-private-plaatsing-af-door-uitgifte-van-2-389-347-nieuwe-aandelen/ 2023-12-10T21:51:48+00:00 https://lakefrontbio.com/press-releases/galapagos-successfully-completes-placement-of-2389347-new-ordinary-shares/ 2023-12-10T21:51:48+00:00 https://lakefrontbio.com/press-releases/galapagos-rondt-plaatsing-van-2-389-347-nieuwe-aandelen-succesvol-af/ 2023-12-10T21:51:48+00:00 https://lakefrontbio.com/press-releases/galapagos-achieves-milestones-in-two-strategic-alliances/ 2023-12-10T21:51:48+00:00 https://lakefrontbio.com/press-releases/galapagos-bereikt-mijlpalen-in-twee-strategische-allianties/ 2023-12-10T21:51:49+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-offering-of-new-ordinary-shares/ 2023-12-10T21:51:49+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-plaatsing-van-nieuwe-aandelen-aan/ 2023-12-10T21:52:02+00:00 https://lakefrontbio.com/press-releases/galapagos-affiliate-biofocus-extends-collaboration-with-chiesi/ 2023-12-10T21:52:02+00:00 https://lakefrontbio.com/press-releases/galapagos-breidt-samenwerking-met-chiesi-uit/ 2023-12-10T21:52:02+00:00 https://lakefrontbio.com/press-releases/galapagos-and-the-national-cancer-institute-sign-compound-management-agreement/ 2023-12-10T21:52:02+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-samenwerken-met-het-amerikaanse-national-cancer-institute/ 2023-12-10T21:52:03+00:00 https://lakefrontbio.com/press-releases/galapagos-wins-2010-european-biotechnica-award/ 2023-12-10T21:52:03+00:00 https://lakefrontbio.com/press-releases/galapagos-wint-2010-european-biotechnica-award/ 2023-12-10T21:52:03+00:00 https://lakefrontbio.com/press-releases/galapagos-affiliate-argenta-and-janssen-pharmaceutica-enter-in-integrated-cancer-drug-discovery-service-agreement/ 2023-12-10T21:52:03+00:00 https://lakefrontbio.com/press-releases/galapagos-divisie-argenta-en-janssen-pharmaceutica-starten-samenwerking-voor-medicijnontwikkeling-in-kanker/ 2023-12-10T21:52:04+00:00 https://lakefrontbio.com/press-releases/galapagos-starts-phase-ii-clinical-trial-in-rheumatoid-arthritis-patients/ 2023-12-10T21:52:04+00:00 https://lakefrontbio.com/press-releases/galapagos-start-fase-ii-klinische-studie-in-reuma-patienten/ 2023-12-10T21:52:04+00:00 https://lakefrontbio.com/press-releases/argenta-expands-collaboration-with-genentech-to-include-biofocus/ 2023-12-10T21:52:04+00:00 https://lakefrontbio.com/press-releases/galapagos-reaches-agreement-to-acquire-glaxosmithkline-research-centre-in-zagreb-croatia/ 2023-12-10T21:52:05+00:00 https://lakefrontbio.com/press-releases/galapagos-bereikt-overeenkomst-voor-overname-research-centrum-glaxosmithkline-in-zagreb-kroatie/ 2023-12-10T21:52:05+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-appointment-of-howard-rowe-to-board-of-directors-increases-share-capital-through-warrant-exercises/ 2023-12-10T21:52:05+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-de-benoeming-aan-van-howard-rowe-als-bestuurder-verhoogt-aandelenkapitaal-door-uitoefenen-van-warrants/ 2023-12-10T21:52:05+00:00 https://lakefrontbio.com/press-releases/galapagos-half-year-results-in-line-with-full-year-guidance/ 2023-12-10T21:52:06+00:00 https://lakefrontbio.com/press-releases/halfjaar-cijfers-van-galapagos-in-lijn-met-de-afgegeven-verwachting-voor-resultaat-voor-het-hele-jaar/ 2023-12-10T21:52:06+00:00 https://lakefrontbio.com/press-releases/galapagos-initiates-phase-i-study-for-jak-inhibitor-glpg0634-acquires-full-rights-to-compound-from-gsk/ 2023-12-10T21:52:06+00:00 https://lakefrontbio.com/press-releases/galapagos-start-fase-i-studie-voor-jak-remmer-glpg0634-verwerft-alle-rechten-op-kandidaat-medicijn-van-gsk/ 2023-12-10T21:52:07+00:00 https://lakefrontbio.com/press-releases/galapagos-and-university-of-bristol-enter-drug-discovery-collaboration-in-chronic-pain/ 2023-12-10T21:52:07+00:00 https://lakefrontbio.com/press-releases/galapagos-en-de-universiteit-van-bristol-gaan-samenwerken-voor-geneesmiddel-tegen-chronische-pijn/ 2023-12-10T21:52:08+00:00 https://lakefrontbio.com/press-releases/nih-extends-agreement-with-galapagos-until-end-2012/ 2023-12-10T21:52:08+00:00 https://lakefrontbio.com/press-releases/nih-verlengt-haar-overeenkomst-met-galapagos/ 2023-12-10T21:52:08+00:00 https://lakefrontbio.com/press-releases/servier-and-galapagos-initiate-strategic-alliance-in-osteoarthritis/ 2023-12-10T21:52:08+00:00 https://lakefrontbio.com/press-releases/servier-en-galapagos-gaan-alliantie-aan-op-gebied-van-artrose/ 2023-12-10T21:52:09+00:00 https://lakefrontbio.com/press-releases/correction-transparency-notification/ 2023-12-10T21:52:09+00:00 https://lakefrontbio.com/press-releases/correctie-kennisgeving-van-belangrijke-deelneming/ 2023-12-10T21:52:09+00:00 https://lakefrontbio.com/press-releases/galapagos-increases-share-capital-through-warrant-exercises-receives-transparency-notifications/ 2023-12-10T21:52:09+00:00 https://lakefrontbio.com/press-releases/galapagos-verhoogt-aandelenkapitaal-door-uitoefenen-van-warrants-ontvangt-kennisgevingen-van-belangrijke-deelnemingen/ 2023-12-10T21:52:09+00:00 https://lakefrontbio.com/press-releases/apax-shareholding-in-galapagos-placed-with-institutional-investors/ 2023-12-10T21:52:10+00:00 https://lakefrontbio.com/press-releases/apax-heeft-haar-aandelen-in-galapagos-aan-institutionele-beleggers-verkocht/ 2023-12-10T21:52:10+00:00 https://lakefrontbio.com/press-releases/galapagos-achieves-milestones-in-osteoporosis-alliance/ 2023-12-10T21:52:10+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-succesbetaling-in-osteoporose-alliantie/ 2023-12-10T21:52:10+00:00 https://lakefrontbio.com/press-releases/galapagos-initiates-clinical-studies-with-glpg0492-a-candidate-drug-for-cachexia/ 2023-12-10T21:52:11+00:00 https://lakefrontbio.com/press-releases/galapagos-start-klinisch-onderzoek-met-glpg0492-een-kandidaat-medicijn-tegen-cachexia/ 2023-12-10T21:52:11+00:00 https://lakefrontbio.com/press-releases/galapagos-business-update-13/ 2023-12-10T21:52:11+00:00 https://lakefrontbio.com/press-releases/galapagos-business-update-14/ 2023-12-10T21:52:12+00:00 https://lakefrontbio.com/press-releases/galapagos-and-roche-expand-copd-alliance/ 2023-12-10T21:52:12+00:00 https://lakefrontbio.com/press-releases/galapagos-en-roche-breiden-copd-alliantie-uit/ 2023-12-10T21:52:12+00:00 https://lakefrontbio.com/press-releases/galapagos-and-chdi-foundation-inc-enter-new-five-year-collaboration-for-huntingtons-disease-therapeutics/ 2023-12-10T21:52:13+00:00 https://lakefrontbio.com/press-releases/galapagos-en-chdi-gaan-nieuwe-samenwerking-voor-ziekte-van-huntington-aan-voor-vijf-jaar/ 2023-12-10T21:52:13+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-appointment-of-ronald-brus-to-board-creates-new-warrant-plans/ 2023-12-10T21:52:13+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-de-benoeming-aan-van-ronald-brus-als-bestuurder-creeert-nieuwe-warrantplannen/ 2023-12-10T21:52:14+00:00 https://lakefrontbio.com/press-releases/galapagos-to-present-glpg0187-first-in-human-trial-results-cancelled/ 2023-12-10T21:52:14+00:00 https://lakefrontbio.com/press-releases/galapagos-to-present-glpg0187-first-in-human-trial-results-at-aacr-annual-meeting-cancelled/ 2023-12-10T21:52:14+00:00 https://lakefrontbio.com/press-releases/galapagos-raises-e2-1-million-from-warrant-exercises-management-increases-shareholding/ 2023-12-10T21:52:14+00:00 https://lakefrontbio.com/press-releases/galapagos-verhoogt-kapitaal-met-e21-miljoen-door-uitoefening-van-warrants-management-breidt-eigen-aandelenpakket-uit/ 2023-12-10T21:52:15+00:00 https://lakefrontbio.com/press-releases/galapagos-to-build-cystic-fibrosis-drug-pipeline/ 2023-12-10T21:52:15+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-geneesmiddel-voor-taaislijmziekte-ontwikkelen/ 2023-12-10T21:52:15+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-record-revenues-and-net-profit-for-2009-foresees-sustained-profitability/ 2023-12-10T21:52:28+00:00 https://lakefrontbio.com/press-releases/galapagos-behaalt-recordomzet-en-netto-winst-in-2009-en-voorziet-aanhoudende-winstgevendheid/ 2023-12-10T21:52:29+00:00 https://lakefrontbio.com/press-releases/galapagos-successfully-completes-phase-i-clinical-trials-for-rheumatoid-arthritis-candidate-drug-glpg0259/ 2023-12-10T21:52:29+00:00 https://lakefrontbio.com/press-releases/galapagos-rondt-fase-i-studies-met-kandidaat-medicijn-glpg0259-tegen-reuma-succesvol-af/ 2023-12-10T21:52:29+00:00 https://lakefrontbio.com/press-releases/galapagos-delivers-third-candidate-drug-in-gsk-alliance-receives-e5-7-million/ 2023-12-10T21:52:30+00:00 https://lakefrontbio.com/press-releases/galapagos-levert-derde-kandidaat-medicijn-in-gsk-alliantie-en-ontvangt-e57-miljoen/ 2023-12-10T21:52:30+00:00 https://lakefrontbio.com/press-releases/transparency-information/ 2023-12-10T21:52:30+00:00 https://lakefrontbio.com/press-releases/kennisgeving-van-belangrijke-deelneming/ 2023-12-10T21:52:30+00:00 https://lakefrontbio.com/press-releases/galapagos-and-morphosys-expand-antibody-alliance/ 2023-12-10T21:52:30+00:00 https://lakefrontbio.com/press-releases/galapagos-neemt-argenta-discovery-servicedivisie-over/ 2023-12-10T21:52:31+00:00 https://lakefrontbio.com/press-releases/galapagos-en-morphosys-breiden-antilichamen-alliantie-uit/ 2023-12-10T21:52:31+00:00 https://lakefrontbio.com/press-releases/galapagos-acquires-argenta-discoverys-service-operations/ 2023-12-10T21:52:31+00:00 https://lakefrontbio.com/press-releases/galapagos-delivers-strong-2009-performance-expects-positive-operating-income-in-2010/ 2023-12-10T21:52:32+00:00 https://lakefrontbio.com/press-releases/galapagos-realiseert-een-sterk-2009-verwacht-een-positief-bedrijfsresultaat-in-2010/ 2023-12-10T21:52:32+00:00 https://lakefrontbio.com/press-releases/galapagos-candidate-metastasis-drug-shows-good-safety-and-biomarker-response/ 2023-12-10T21:52:32+00:00 https://lakefrontbio.com/press-releases/galapagos-kandidaat-medicijn-tegen-metastase-neemt-een-veelbelovende-start-in-klinisch-onderzoek/ 2023-12-10T21:52:32+00:00 https://lakefrontbio.com/press-releases/galapagos-achieves-milestones-in-strategic-alliances-with-merck-co-inc/ 2023-12-10T21:52:32+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-succesbetalingen-in-strategische-allianties-met-merck-co-inc/ 2023-12-10T21:52:33+00:00 https://lakefrontbio.com/press-releases/galapagos-service-division-achieves-eur-1-6-m-in-payments/ 2023-12-10T21:52:33+00:00 https://lakefrontbio.com/press-releases/galapagos-service-divisie-ontvangt-eur-16-miljoen-succesbetaling/ 2023-12-10T21:52:33+00:00 https://lakefrontbio.com/press-releases/galapagos-and-roche-initiate-strategic-alliance-in-copd/ 2023-12-10T21:52:34+00:00 https://lakefrontbio.com/press-releases/galapagos-en-roche-gaan-strategische-alliantie-aan-op-gebied-van-copd/ 2023-12-10T21:52:34+00:00 https://lakefrontbio.com/press-releases/galapagos-and-glaxosmithkline-broaden-arthritis-alliance/ 2023-12-10T21:52:34+00:00 https://lakefrontbio.com/press-releases/galapagos-en-glaxosmithkline-breiden-artritis-alliantie-verder-uit/ 2023-12-10T21:52:35+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-e4-m-milestone-for-first-clinical-trial-in-glaxosmithkline-alliance/ 2023-12-10T21:52:35+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-e4-miljoen-succesbetaling-voor-eerste-klinische-studie-binnen-de-glaxosmithkline-alliantie/ 2023-12-10T21:52:35+00:00 https://lakefrontbio.com/press-releases/galapagos-ceo-increases-shareholding/ 2023-12-10T21:52:35+00:00 https://lakefrontbio.com/press-releases/ceo-galapagos-breidt-aandelenpakket-uit/ 2023-12-10T21:52:35+00:00 https://lakefrontbio.com/press-releases/galapagos-achieves-multiple-milestones-in-rheumatoid-arthritis-alliance/ 2023-12-10T21:52:36+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-e102-miljoen-aan-succesbetalingen-in-reuma-alliantie-met-janssen/ 2023-12-10T21:52:36+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-eureka-innovation-label-and-oseo-funding/ 2023-12-10T21:52:36+00:00 https://lakefrontbio.com/press-releases/galapagos-krijgt-eureka-innovatie-label-en-oseo-funding/ 2023-12-10T21:52:36+00:00 https://lakefrontbio.com/press-releases/galapagos-initiates-nanocort-phase-ii-clinical-trial-for-multiple-sclerosis/ 2023-12-10T21:52:37+00:00 https://lakefrontbio.com/press-releases/galapagos-start-fase-ii-klinische-studie-met-nanocort-tegen-multiple-sclerose/ 2023-12-10T21:52:37+00:00 https://lakefrontbio.com/press-releases/galapagos-business-update-15/ 2023-12-10T21:52:37+00:00 https://lakefrontbio.com/press-releases/galapagos-business-update-16/ 2023-12-10T21:52:37+00:00 https://lakefrontbio.com/press-releases/galapagos-successfully-completes-placement-of-2125925-new-ordinary-shares/ 2023-12-10T21:52:38+00:00 https://lakefrontbio.com/press-releases/galapagos-rondt-plaatsing-van-2-125-925-nieuwe-aandelen-succesvol-af/ 2023-12-10T21:52:38+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-plaatsing-van-nieuwe-aandelen-aan-2/ 2023-12-10T21:52:38+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-offering-of-new-ordinary-shares-2/ 2023-12-10T21:52:38+00:00 https://lakefrontbio.com/press-releases/galapagos-expands-strategic-alliance-in-metabolic-disease-with-merck-co-inc/ 2023-12-10T21:52:39+00:00 https://lakefrontbio.com/press-releases/galapagos-in-atherosclerose-alliantie-met-merck-co-inc/ 2023-12-10T21:52:39+00:00 https://lakefrontbio.com/press-releases/galapagos-achieves-first-milestone-in-anti-infectives-alliance-with-glaxosmithkline/ 2023-12-10T21:52:40+00:00 https://lakefrontbio.com/press-releases/galapagos-bereikt-eerste-mijlpaal-in-alliantie-met-glaxosmithkline-in-infectieziekten/ 2023-12-10T21:52:40+00:00 https://lakefrontbio.com/press-releases/investor-relations-update-fall-2009/ 2023-12-10T21:52:40+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-expanded-drug-discovery-collaboration-with-schering-plough/ 2023-12-10T21:52:41+00:00 https://lakefrontbio.com/press-releases/galapagos-en-schering-plough-gaan-brede-samenwerking-aan-in-medicijnontwikkeling/ 2023-12-10T21:52:41+00:00 https://lakefrontbio.com/press-releases/galapagos-collaborates-with-charleys-fund-nash-avery-foundation-to-develop-sarm-candidate-drug-for-duchenne-muscular-dystrophy/ 2023-12-10T21:52:41+00:00 https://lakefrontbio.com/press-releases/galapagos-ontwikkelt-kandidaat-medicijn-tegen-spierdystrofie-in-samenwerking-met-charleys-fund-nash-avery-foundation/ 2023-12-10T21:52:41+00:00 https://lakefrontbio.com/press-releases/galapagos-initiates-second-phase-i-clinical-trial-for-glpg0259/ 2023-12-10T21:52:42+00:00 https://lakefrontbio.com/press-releases/galapagos-start-tweede-fase-i-studie-met-glpg0259/ 2023-12-10T21:52:54+00:00 https://lakefrontbio.com/press-releases/sterke-omzetstijging-en-verbetering-van-netto-resultaat-voor-galapagos-in-het-eerste-halfjaar-van-2009/ 2023-12-10T21:52:55+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-revenue-growth-and-improved-net-result-in-1h-2009/ 2023-12-10T21:52:55+00:00 https://lakefrontbio.com/press-releases/galapagos-successfully-completes-first-phase-i-study-for-glpg0259/ 2023-12-10T21:52:55+00:00 https://lakefrontbio.com/press-releases/galapagos-rondt-eerste-fase-i-studie-met-glpg0259-succesvol-af/ 2023-12-10T21:52:56+00:00 https://lakefrontbio.com/press-releases/galapagos-achieves-milestone-in-osteoporosis-collaboration-with-lilly/ 2023-12-10T21:52:56+00:00 https://lakefrontbio.com/press-releases/galapagos-bereikt-mijlpaal-in-osteoporose-alliantie-met-lilly/ 2023-12-10T21:52:56+00:00 https://lakefrontbio.com/press-releases/galapagos-delivers-second-pre-clinical-candidate-in-alliance-with-glaxosmithkline-and-receives-e5-2-million-in-milestone-payments/ 2023-12-10T21:52:56+00:00 https://lakefrontbio.com/press-releases/galapagos-levert-tweede-preklinisch-kandidaat-medicijn-in-alliantie-met-glaxosmithkline-en-ontvangt-e52-miljoen/ 2023-12-10T21:52:57+00:00 https://lakefrontbio.com/press-releases/qualification-dentreprise-innovante-au-titre-des-fcpi-attribuee-a-galapagos/ 2023-12-10T21:52:57+00:00 https://lakefrontbio.com/press-releases/galapagos-awarded-innovative-enterprise-qualification-in-france/ 2023-12-10T21:52:57+00:00 https://lakefrontbio.com/press-releases/qualification-dentreprise-innovante-au-titre-des-fcpi-attribuee-a-galapagos-2/ 2023-12-10T21:52:57+00:00 https://lakefrontbio.com/press-releases/galapagos-krijgt-status-innoverende-onderneming-in-frankrijk/ 2023-12-10T21:52:57+00:00 https://lakefrontbio.com/press-releases/galapagos-initiates-clinical-studies-with-glpg0187-a-candidate-drug-for-bone-metastasis/ 2023-12-10T21:52:58+00:00 https://lakefrontbio.com/press-releases/galapagos-start-klinisch-onderzoek-met-glpg0187-een-kandidaat-medicijn-tegen-botkanker/ 2023-12-10T21:52:58+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-appointment-of-new-cfo-and-board-member-creates-new-warrant-plan/ 2023-12-10T21:52:58+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-de-aanstelling-aan-van-een-nieuwe-cfo-en-een-nieuwe-bestuurder-creeert-nieuw-warrantplan/ 2023-12-10T21:52:58+00:00 https://lakefrontbio.com/press-releases/galapagos-achieves-milestone-payment-in-rheumatoid-arthritis-alliance/ 2023-12-10T21:52:59+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-succesbetaling-in-reuma-alliantie-met-janssen/ 2023-12-10T21:52:59+00:00 https://lakefrontbio.com/press-releases/galapagos-business-update-17/ 2023-12-10T21:52:59+00:00 https://lakefrontbio.com/press-releases/galapagos-business-update-18/ 2023-12-10T21:53:00+00:00 https://lakefrontbio.com/press-releases/galapagos-and-opsona-therapeutics-initiate-drug-discovery-collaboration/ 2023-12-10T21:53:00+00:00 https://lakefrontbio.com/press-releases/galapagos-en-opsona-therapeutics-starten-samenwerking-op-gebied-van-medicijnontwikkeling/ 2023-12-10T21:53:00+00:00 https://lakefrontbio.com/press-releases/galapagos-enters-strategic-alliance-in-inflammatory-diseases-with-merck-co-inc/ 2023-12-10T21:53:01+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-alliantie-aan-met-merck-co-inc-in-ontstekingsziekten/ 2023-12-10T21:53:01+00:00 https://lakefrontbio.com/press-releases/galapagos-creates-new-warrant-plan-11/ 2023-12-10T21:53:01+00:00 https://lakefrontbio.com/press-releases/galapagos-creeert-nieuw-warrantplan-12/ 2023-12-10T21:53:01+00:00 https://lakefrontbio.com/press-releases/galapagos-enters-the-clinic-with-rheumatoid-arthritis-candidate-drug/ 2023-12-10T21:53:02+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-de-kliniek-in-met-kandidaat-medicijn-tegen-reuma/ 2023-12-10T21:53:02+00:00 https://lakefrontbio.com/press-releases/galapagos-to-present-rd-update-on-27-march-2009/ 2023-12-10T21:53:02+00:00 https://lakefrontbio.com/press-releases/galapagos-geeft-rd-update-op-27-maart-2009/ 2023-12-10T21:53:02+00:00 https://lakefrontbio.com/press-releases/galapagos-confirms-2008-financial-results-foresees-strong-growth-in-2009/ 2023-12-10T21:53:02+00:00 https://lakefrontbio.com/press-releases/galapagos-presenteert-financiele-resultaten-2008-en-voorziet-sterke-groei-in-2009/ 2023-12-10T21:53:03+00:00 https://lakefrontbio.com/press-releases/galapagos-reveals-key-drug-target-for-alzheimers-disease/ 2023-12-10T21:53:03+00:00 https://lakefrontbio.com/press-releases/sleutelrol-voor-galapagos-medicijn-target-bij-ziekte-van-alzheimer/ 2023-12-10T21:53:03+00:00 https://lakefrontbio.com/press-releases/galapagos-awarded-grant-to-accelerate-drug-discovery/ 2023-12-10T21:53:04+00:00 https://lakefrontbio.com/press-releases/galapagos-krijgt-subsidie-voor-medicijnontwikkeling/ 2023-12-10T21:53:04+00:00 https://lakefrontbio.com/press-releases/galapagos-2008-trading-update-and-2009-guidance/ 2023-12-10T21:53:04+00:00 https://lakefrontbio.com/press-releases/galapagos-cijfers-2008-en-verwachtingen-2009/ 2023-12-10T21:53:04+00:00 https://lakefrontbio.com/press-releases/galapagos-and-glaxosmithkline-expand-anti-infectives-alliance/ 2023-12-10T21:53:05+00:00 https://lakefrontbio.com/press-releases/galapagos-en-glaxosmithkline-breiden-alliantie-in-infectieziekten-uit/ 2023-12-10T21:53:05+00:00 https://lakefrontbio.com/press-releases/galapagos-achieves-milestone-payments-for-rheumatoid-arthritis-alliance/ 2023-12-10T21:53:06+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-e375-miljoen-succesbetaling-in-reuma-alliantie-met-janssen/ 2023-12-10T21:53:06+00:00 https://lakefrontbio.com/press-releases/galapagos-enters-strategic-alliance-in-diabetes-and-obesity-with-merck-co-inc/ 2023-12-10T21:53:06+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-alliantie-aan-met-merck-co-inc-in-diabetes-en-obesitas/ 2023-12-10T21:53:06+00:00 https://lakefrontbio.com/press-releases/galapagos-delivers-pre-clinical-candidate-drug-in-alliance-with-glaxosmithkline-and-receives-e7-6-million-in-milestone-payments/ 2023-12-10T21:53:06+00:00 https://lakefrontbio.com/press-releases/galapagos-levert-preklinisch-kandidaat-medicijn-in-alliantie-met-glaxosmithkline-en-ontvangt-e76-miljoen/ 2023-12-10T21:53:07+00:00 https://lakefrontbio.com/press-releases/galapagos-selects-pre-clinical-candidate-drug-for-cachexia/ 2023-12-10T21:53:07+00:00 https://lakefrontbio.com/press-releases/galapagos-selecteert-preklinisch-kandidaat-medicijn-voor-cachexia/ 2023-12-10T21:53:07+00:00 https://lakefrontbio.com/press-releases/transparency-information-2/ 2023-12-10T21:53:07+00:00 https://lakefrontbio.com/press-releases/transparantieverklaring-9/ 2023-12-10T21:53:26+00:00 https://lakefrontbio.com/press-releases/galapagos-and-glaxosmithkline-expand-osteoarthritis-alliance/ 2023-12-10T21:53:27+00:00 https://lakefrontbio.com/press-releases/galapagos-en-glaxosmithkline-breiden-artrose-alliantie-uit/ 2023-12-10T21:53:27+00:00 https://lakefrontbio.com/press-releases/galapagos-extends-drug-discovery-collaboration-with-amgen-into-2010/ 2023-12-10T21:53:27+00:00 https://lakefrontbio.com/press-releases/galapagos-en-amgen-breiden-samenwerking-uit-tot-in-2010/ 2023-12-10T21:53:27+00:00 https://lakefrontbio.com/press-releases/galapagos-and-dart-neuroscience-llc-sign-drug-discovery-and-compound-management-agreements/ 2023-12-10T21:53:28+00:00 https://lakefrontbio.com/press-releases/galapagos-en-dart-neuroscience-llc-tekenen-overeenkomst-voor-medicijnontwikkeling-en-beheer-van-molecuul-collecties/ 2023-12-10T21:53:28+00:00 https://lakefrontbio.com/press-releases/morphosys-and-galapagos-enter-alliance-to-co-develop-novel-therapeutic-antibodies-in-bone-joint-disease/ 2023-12-10T21:53:28+00:00 https://lakefrontbio.com/press-releases/morphosys-et-galapagos-concluent-une-alliance-de-co-developpement-de-nouveaux-anticorps-therapeutiques-pour-le-traitement-des-maladies-articulaires-et-osseuses/ 2023-12-10T21:53:28+00:00 https://lakefrontbio.com/press-releases/galapagos-en-morphosys-gaan-gezamenlijk-antilichaam-medicijnen-ontwikkelen-voor-bot-en-gewrichtsziekten/ 2023-12-10T21:53:29+00:00 https://lakefrontbio.com/press-releases/galapagos-and-merck-serono-enter-new-collaboration-agreements/ 2023-12-10T21:53:29+00:00 https://lakefrontbio.com/press-releases/galapagos-en-merck-serono-gaan-nieuwe-samenwerkingen-aan/ 2023-12-10T21:53:29+00:00 https://lakefrontbio.com/press-releases/galapagos-business-update-19/ 2023-12-10T21:53:29+00:00 https://lakefrontbio.com/press-releases/galapagos-business-update-20/ 2023-12-10T21:53:29+00:00 https://lakefrontbio.com/press-releases/galapagos-sells-san-diego-chemistry-facility-to-chemventures/ 2023-12-10T21:53:30+00:00 https://lakefrontbio.com/press-releases/galapagos-verkoopt-san-diego-vestiging-aan-chemventures/ 2023-12-10T21:53:30+00:00 https://lakefrontbio.com/press-releases/galapagos-and-chdi-enter-new-collaboration-agreements/ 2023-12-10T21:53:30+00:00 https://lakefrontbio.com/press-releases/galapagos-en-chdi-sluiten-nieuwe-samenwerkingsovereenkomsten/ 2023-12-10T21:53:30+00:00 https://lakefrontbio.com/press-releases/nanocort-demonstrates-safety-and-good-response-in-phase-i-ii-trial/ 2023-12-10T21:53:31+00:00 https://lakefrontbio.com/press-releases/positieve-resultaten-nanocort-fase-i-ii-studie/ 2023-12-10T21:53:31+00:00 https://lakefrontbio.com/press-releases/delta-lloyd-acquires-5-4-of-galapagos/ 2023-12-10T21:53:31+00:00 https://lakefrontbio.com/press-releases/delta-lloyd-heeft-54-van-de-aandelen-van-galapagos/ 2023-12-10T21:53:32+00:00 https://lakefrontbio.com/press-releases/informatie-volgens-transparantiewetgeving-galapagos-nv/ 2023-12-10T21:53:32+00:00 https://lakefrontbio.com/press-releases/transparency-information-galapagos-nv/ 2023-12-10T21:53:32+00:00 https://lakefrontbio.com/press-releases/galapagos-acquires-structure-based-drug-discovery-from-sareum/ 2023-12-10T21:53:32+00:00 https://lakefrontbio.com/press-releases/galapagos-neemt-drug-discovery-business-over-van-sareum/ 2023-12-10T21:53:33+00:00 https://lakefrontbio.com/press-releases/ucb-transfers-uk-based-medicinal-chemistry-program-to-biofocus-dpi/ 2023-12-10T21:53:33+00:00 https://lakefrontbio.com/press-releases/ucb-draagt-medicinaal-chemie-programma-in-de-uk-over-aan-biofocus-dpi/ 2023-12-10T21:53:33+00:00 https://lakefrontbio.com/press-releases/strong-revenue-growth-and-sharp-improvement-of-net-result-for-galapagos-in-1h-2008/ 2023-12-10T21:53:33+00:00 https://lakefrontbio.com/press-releases/sterke-omzetstijging-en-scherpe-verbetering-van-netto-resultaat-voor-galapagos-in-het-eerste-halfjaar-van-2008/ 2023-12-10T21:53:34+00:00 https://lakefrontbio.com/press-releases/galapagos-draagt-databases-voor-medicijnonderzoek-over-aan-europees-bioinformatica-instituut-embl-ebi/ 2023-12-10T21:53:34+00:00 https://lakefrontbio.com/press-releases/galapagos-transfers-predictive-drug-discovery-databases-to-embls-european-bioinformatics-institute/ 2023-12-10T21:53:34+00:00 https://lakefrontbio.com/press-releases/nih-verlengt-haar-overeenkomst-met-galapagos-2/ 2023-12-10T21:53:35+00:00 https://lakefrontbio.com/press-releases/nih-extends-agreement-with-galapagos/ 2023-12-10T21:53:35+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-first-milestone-in-osteoporosis-collaboration-with-lilly/ 2023-12-10T21:53:35+00:00 https://lakefrontbio.com/press-releases/galapagos-verkrijgt-eerste-succesbetaling-in-osteoporose-alliantie-met-lilly/ 2023-12-10T21:53:35+00:00 https://lakefrontbio.com/press-releases/boehringer-ingelheim-licenseert-medicijn-targets-van-galapagos-op-gebied-van-auto-immuunziekten/ 2023-12-10T21:53:36+00:00 https://lakefrontbio.com/press-releases/boehringer-ingelheim-licenses-drug-targets-from-autoimmune-collaboration-with-galapagos/ 2023-12-10T21:53:36+00:00 https://lakefrontbio.com/press-releases/galapagos-creates-new-warrant-plans-5/ 2023-12-10T21:53:36+00:00 https://lakefrontbio.com/press-releases/galapagos-creeert-nieuwe-warrantplannen-3/ 2023-12-10T21:53:36+00:00 https://lakefrontbio.com/press-releases/galapagos-signs-new-compound-management-agreement/ 2023-12-10T21:53:37+00:00 https://lakefrontbio.com/press-releases/galapagos-tekent-beheersovereenkomst-voor-molecuul-collectie-sepracor/ 2023-12-10T21:53:37+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-succesbetaling-van-e08-miljoen-in-artrose-alliantie-met-glaxosmithkline/ 2023-12-10T21:53:37+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-milestone-payment-of-e0-8-million-in-osteoarthritis-alliance-with-glaxosmithkline/ 2023-12-10T21:53:38+00:00 https://lakefrontbio.com/press-releases/william-garth-rapeport-treedt-toe-tot-de-raad-van-bestuur-van-galapagos/ 2023-12-10T21:53:38+00:00 https://lakefrontbio.com/press-releases/william-garth-rapeport-joins-galapagos-board-of-directors/ 2023-12-10T21:53:38+00:00 https://lakefrontbio.com/press-releases/galapagos-tekent-onderzoeksovereenkomst-met-ucl/ 2023-12-10T21:53:38+00:00 https://lakefrontbio.com/press-releases/galapagos-signs-research-agreement-with-ucl/ 2023-12-10T21:53:39+00:00 https://lakefrontbio.com/press-releases/galapagos-business-update-21/ 2023-12-10T21:53:39+00:00 https://lakefrontbio.com/press-releases/galapagos-business-update-22/ 2023-12-10T21:53:39+00:00 https://lakefrontbio.com/press-releases/galapagos-and-allergan-enter-drug-discovery-collaboration/ 2023-12-10T21:53:52+00:00 https://lakefrontbio.com/press-releases/galapagos-en-allergan-tekenen-drug-discovery-contract/ 2023-12-10T21:53:52+00:00 https://lakefrontbio.com/press-releases/galapagos-verkrijgt-klinisch-reuma-programma/ 2023-12-10T21:53:52+00:00 https://lakefrontbio.com/press-releases/galapagos-licenses-clinical-rheumatoid-arthritis-program/ 2023-12-10T21:53:52+00:00 https://lakefrontbio.com/press-releases/galapagos-benoemt-piet-wigerinck-tot-senior-vp-development/ 2023-12-10T21:53:53+00:00 https://lakefrontbio.com/press-releases/galapagos-appoints-piet-wigerinck-as-senior-vp-development/ 2023-12-10T21:53:53+00:00 https://lakefrontbio.com/press-releases/bausch-lomb-en-galapagos-tekenen-samenwerkingsovereenkomst-op-gebied-van-oogziektes/ 2023-12-10T21:53:53+00:00 https://lakefrontbio.com/press-releases/bausch-lomb-and-galapagos-sign-agreement-to-collaborate-on-ophthalmic-disease-research/ 2023-12-10T21:53:53+00:00 https://lakefrontbio.com/press-releases/galapagos-nv-director-pdmr-shareholding/ 2023-12-10T21:53:54+00:00 https://lakefrontbio.com/press-releases/galapagos-adr-notering-nu-actief-ceo-geeft-presentatie-op-cowen-health-care-conference-in-de-vs/ 2023-12-10T21:53:54+00:00 https://lakefrontbio.com/press-releases/galapagos-adr-listing-operational-ceo-presents-at-cowen-health-care-conference-in-the-u-s/ 2023-12-10T21:53:54+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-2007-full-year-results/ 2023-12-10T21:53:54+00:00 https://lakefrontbio.com/press-releases/galapagos-maakt-resultaten-2007-bekend/ 2023-12-10T21:53:55+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-level-1-adr-listing-and-cancels-aim-listing/ 2023-12-10T21:53:55+00:00 https://lakefrontbio.com/press-releases/galapagos-verkrijgt-amerikaanse-level-1-adr-notering-en-heft-aim-notering-op/ 2023-12-10T21:53:55+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-pre-klinische-kandidaat-medicijnen-aan-en-licht-klinische-plannen-toe-op-gebied-van-reuma-en-bot-metastase/ 2023-12-10T21:53:55+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-pre-clinical-candidates-and-clinical-plans-in-rheumatoid-arthritis-and-bone-metastasis/ 2023-12-10T21:53:55+00:00 https://lakefrontbio.com/press-releases/galapagos-trading-update/ 2023-12-10T21:53:56+00:00 https://lakefrontbio.com/press-releases/galapagos-cijfers/ 2023-12-10T21:53:56+00:00 https://lakefrontbio.com/press-releases/galapagos-achieves-e3-4-million-milestone-payment-from-janssen-pharmaceutica-nv/ 2023-12-10T21:53:56+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-e34-miljoen-succesbetaling-uit-alliantie-met-janssen-pharmaceutica-nv/ 2023-12-10T21:53:57+00:00 https://lakefrontbio.com/press-releases/galapagos-geeft-rd-update-op-28-februari-2008/ 2023-12-10T21:53:57+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-rd-update-on-28-february-2008/ 2023-12-10T21:53:57+00:00 https://lakefrontbio.com/press-releases/galapagos-awarded-e4-4-m-grant-for-rheumatoid-arthritis-drug-development/ 2023-12-10T21:53:58+00:00 https://lakefrontbio.com/press-releases/galapagos-krijgt-e44-miljoen-subsidie-voor-ontwikkelen-van-reuma-geneesmiddel/ 2023-12-10T21:53:58+00:00 https://lakefrontbio.com/press-releases/galapagos-verlengt-samenwerking-met-lilly-uit-op-het-gebied-van-hormoon-receptoren/ 2023-12-10T21:53:58+00:00 https://lakefrontbio.com/press-releases/galapagos-extends-drug-discovery-collaboration-with-lilly-in-nuclear-hormone-receptor-research/ 2023-12-10T21:53:58+00:00 https://lakefrontbio.com/press-releases/galapagos-enters-into-oncology-target-discovery-collaboration-with-janssen-pharmaceutica/ 2023-12-10T21:53:59+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-samenwerking-aan-met-janssen-pharmaceutica-op-gebied-van-kankeronderzoek/ 2023-12-10T21:53:59+00:00 https://lakefrontbio.com/press-releases/additional-listing/ 2023-12-10T21:53:59+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-osteoporosis-collaboration-with-lilly/ 2023-12-10T21:53:59+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-alliantie-aan-met-lilly-voor-osteoporose/ 2023-12-10T21:54:00+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-milestone-payment-of-e7-5-million-in-osteoarthritis-alliance-with-glaxosmithkline/ 2023-12-10T21:54:00+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-succesbetaling-van-e75-miljoen-in-artrose-alliantie-met-glaxosmithkline/ 2023-12-10T21:54:00+00:00 https://lakefrontbio.com/press-releases/director-shareholding/ 2023-12-10T21:54:00+00:00 https://lakefrontbio.com/press-releases/glaxosmithkline-en-galapagos-gaan-strategische-alliantie-aan-voor-nieuwe-antibiotica-en-antivirale-middelen/ 2023-12-10T21:54:01+00:00 https://lakefrontbio.com/press-releases/glaxosmithkline-and-galapagos-enter-strategic-alliance-to-develop-novel-antibacterials-and-antivirals/ 2023-12-10T21:54:01+00:00 https://lakefrontbio.com/press-releases/galapagos-and-cystic-fibrosis-foundation-therapeutics-announce-new-drug-discovery-collaboration-worth-up-to-8-1-million-u-s-dollars/ 2023-12-10T21:54:01+00:00 https://lakefrontbio.com/press-releases/galapagos-en-cystic-fibrosis-foundation-therapeutics-kondigen-nieuwe-samenwerking-aan-voor-een-totaal-bedrag-tot-e55-miljoen/ 2023-12-10T21:54:01+00:00 https://lakefrontbio.com/press-releases/director-pdmr-shareholding/ 2023-12-10T21:54:02+00:00 https://lakefrontbio.com/press-releases/galapagos-creates-new-warrant-plan-12/ 2023-12-10T21:54:02+00:00 https://lakefrontbio.com/press-releases/galapagos-creeert-nieuw-warrantplan-13/ 2023-12-10T21:54:03+00:00 https://lakefrontbio.com/press-releases/galapagos-verhoogt-omzetverwachting-en-eindejaar-kaspositie-voor-2007/ 2023-12-10T21:54:03+00:00 https://lakefrontbio.com/press-releases/galapagos-enters-into-global-alliance-with-janssen-pharmaceutica-on-rheumatoid-arthritis-research/ 2023-12-10T21:54:03+00:00 https://lakefrontbio.com/press-releases/galapagos-revises-2007-financial-guidance/ 2023-12-10T21:54:03+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-wereldwijde-overeenkomst-aan-met-janssen-pharmaceutica-op-gebied-van-reuma/ 2023-12-10T21:54:04+00:00 https://lakefrontbio.com/press-releases/galapagos-krijgt-e52-miljoen-subsidie-toegekend/ 2023-12-10T21:54:04+00:00 https://lakefrontbio.com/press-releases/galapagos-awarded-e5-2-million-in-research-grants/ 2023-12-10T21:54:04+00:00 https://lakefrontbio.com/press-releases/galapagos-and-prostrakan-receive-additional-milestone-payment-in-antibody-collaboration/ 2023-12-10T21:54:05+00:00 https://lakefrontbio.com/press-releases/galapagos-en-prostrakan-ontvangen-mijlpaalbetaling-in-samenwerking-op-gebied-van-antilichamen/ 2023-12-10T21:54:05+00:00 https://lakefrontbio.com/press-releases/aim-rule-26/ 2023-12-10T21:54:18+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-expanded-relationship-with-astrazeneca-biofocus-dpi-to-provide-drug-discovery-services-to-us-site/ 2023-12-10T21:54:19+00:00 https://lakefrontbio.com/press-releases/sharp-revenue-increase-and-strong-progress-in-research-programs-for-galapagos-in-the-first-half-year-2007/ 2023-12-10T21:54:19+00:00 https://lakefrontbio.com/press-releases/sterke-omzetstijging-en-grote-vooruitgang-in-researchprogrammas-voor-galapagos-in-het-eerste-halfjaar-2007/ 2023-12-10T21:54:19+00:00 https://lakefrontbio.com/press-releases/galapagos-breidt-samenwerking-met-astrazeneca-verder-uit-met-nieuwe-drug-discovery-services-voor-vs-vestiging/ 2023-12-10T21:54:19+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-milestone-payment-in-antibody-collaboration/ 2023-12-10T21:54:20+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-mijlpaalbetaling-in-samenwerking-op-gebied-van-antilichamen/ 2023-12-10T21:54:20+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-milestone-in-collaboration-with-boehringer-ingelheim/ 2023-12-10T21:54:20+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-mijlpaal-betaling-in-samenwerking-met-boehringer-ingelheim/ 2023-12-10T21:54:20+00:00 https://lakefrontbio.com/press-releases/additional-listing-2/ 2023-12-10T21:54:21+00:00 https://lakefrontbio.com/press-releases/galapagos-expands-osteoarthritis-alliance-with-glaxosmithkline-gsk-makes-e4-4-million-equity-investment-in-galapagos/ 2023-12-10T21:54:21+00:00 https://lakefrontbio.com/press-releases/galapagos-breidt-artrose-alliantie-met-glaxosmithkline-uit-gsk-investeert-e44-miljoen-in-galapagos-aandelen/ 2023-12-10T21:54:21+00:00 https://lakefrontbio.com/press-releases/galapagos-creeert-nieuw-warrantplan-14/ 2023-12-10T21:54:21+00:00 https://lakefrontbio.com/press-releases/galapagos-creates-new-warrant-plan-13/ 2023-12-10T21:54:22+00:00 https://lakefrontbio.com/press-releases/director-shareholding-2/ 2023-12-10T21:54:22+00:00 https://lakefrontbio.com/press-releases/wyeth-licenses-drug-targets-from-osteoporosis-collaboration-with-galapagos/ 2023-12-10T21:54:22+00:00 https://lakefrontbio.com/press-releases/wyeth-licentieert-drug-targets-uit-de-samenwerking-met-galapagos-op-gebied-van-botontkalking/ 2023-12-10T21:54:22+00:00 https://lakefrontbio.com/press-releases/galapagos-to-present-at-piper-jaffray-health-care-conference/ 2023-12-10T21:54:22+00:00 https://lakefrontbio.com/press-releases/galapagos-presentatie-bij-piper-jaffray-health-care-conference/ 2023-12-10T21:54:23+00:00 https://lakefrontbio.com/press-releases/additional-listing-3/ 2023-12-10T21:54:23+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-new-collaboration-agreements-and-a-management-appointment/ 2023-12-10T21:54:23+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-nieuwe-samenwerkingsovereenkomsten-en-de-benoeming-van-een-senior-medewerker-aan/ 2023-12-10T21:54:24+00:00 https://lakefrontbio.com/press-releases/galapagos-voltooit-de-aandelenuitgiftes-voor-de-overname-van-inpharmatica/ 2023-12-10T21:54:24+00:00 https://lakefrontbio.com/press-releases/galapagos-completes-final-share-issue-for-inpharmatica-acquisition/ 2023-12-10T21:54:24+00:00 https://lakefrontbio.com/press-releases/galapagos-and-astrazeneca-enter-new-drug-discovery-collaboration/ 2023-12-10T21:54:24+00:00 https://lakefrontbio.com/press-releases/galapagos-en-astrazeneca-tekenen-nieuwe-drug-discovery-overeenkomst/ 2023-12-10T21:54:24+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-agreement-worth-up-to-e6-3-million-with-united-states-environmental-protection-agency-epa/ 2023-12-10T21:54:25+00:00 https://lakefrontbio.com/press-releases/galapagos-tekent-overeenkomst-voor-maximaal-e63-miljoen-met-amerikaanse-environmental-protection-agency-epa/ 2023-12-10T21:54:25+00:00 https://lakefrontbio.com/press-releases/galapagos-signs-two-new-drug-discovery-collaborations-with-ono-pharmaceutical/ 2023-12-10T21:54:25+00:00 https://lakefrontbio.com/press-releases/galapagos-tekent-twee-nieuwe-samenwerkingsovereenkomsten-met-ono-pharmaceutical/ 2023-12-10T21:54:25+00:00 https://lakefrontbio.com/press-releases/galapagos-issues-628058-new-shares-related-to-inpharmatica-acquisition-and-warrant-exercise/ 2023-12-10T21:54:25+00:00 https://lakefrontbio.com/press-releases/galapagos-geeft-628-058-nieuwe-aandelen-uit-in-verband-met-de-overname-van-inpharmatica-en-de-uitoefening-van-warranten/ 2023-12-10T21:54:26+00:00 https://lakefrontbio.com/press-releases/extraordinary-general-meeting-of-shareholders/ 2023-12-10T21:54:26+00:00 https://lakefrontbio.com/press-releases/galapagos-publiceert-2006-prospectus-en-kondigt-managementwissel-aan/ 2023-12-10T21:54:26+00:00 https://lakefrontbio.com/press-releases/galapagos-verkrijgt-succesbetaling-van-e32-miljoen-in-artrose-alliantie-met-glaxosmithkline/ 2023-12-10T21:54:26+00:00 https://lakefrontbio.com/press-releases/galapagos-publishes-2006-prospectus-and-announces-management-change/ 2023-12-10T21:54:27+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-achievement-of-milestones-totaling-e3-2-million-in-osteoarthritis-alliance-with-glaxosmithkline/ 2023-12-10T21:54:27+00:00 https://lakefrontbio.com/press-releases/additional-listing-4/ 2023-12-10T21:54:27+00:00 https://lakefrontbio.com/press-releases/convocation-of-shareholders-meeting/ 2023-12-10T21:54:27+00:00 https://lakefrontbio.com/press-releases/galapagos-to-supply-chemical-compound-sets-to-johnson-johnson-pharmaceutical-research-development-division-of-janssen-pharmaceutica-nv/ 2023-12-10T21:54:28+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-chemische-molecuulcollecties-leveren-aan-johnson-johnson-pharmaceutical-research-development-divisie-van-janssen-pharmaceutica-nv/ 2023-12-10T21:54:28+00:00 https://lakefrontbio.com/press-releases/galapagos-maakt-resultaten-2006-bekend/ 2023-12-10T21:54:28+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-2006-full-year-results/ 2023-12-10T21:54:29+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-2006-full-year-results-2/ 2023-12-10T21:54:29+00:00 https://lakefrontbio.com/press-releases/galapagos-maakt-resultaten-2006-bekend-2/ 2023-12-10T21:54:29+00:00 https://lakefrontbio.com/press-releases/galapagos-and-the-university-of-bristol-enter-drug-discovery-collaboration/ 2023-12-10T21:54:29+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-drug-discovery-samenwerking-aan-met-de-universiteit-van-bristol/ 2023-12-10T21:54:30+00:00 https://lakefrontbio.com/press-releases/director-pdmr-shareholding-2/ 2023-12-10T21:54:30+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-ppar-delta-commercial-license-agreement-with-hillcrest-therapeutics/ 2023-12-10T21:54:30+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-commerciele-licentieovereenkomst-voor-ppar-delta-aan-met-hillcrest-therapeutics/ 2023-12-10T21:54:30+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-2006-financial-update-drug-discovery-advancements-and-changes-to-board-of-directors/ 2023-12-10T21:54:42+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-2006-financial-update-drug-discovery-advancements-and-changes-to-board-of-directors-2/ 2023-12-10T21:54:42+00:00 https://lakefrontbio.com/press-releases/galapagos-geeft-update-over-2006-financien-onderzoeksprogramma-en-samenstelling-raad-van-bestuur/ 2023-12-10T21:54:43+00:00 https://lakefrontbio.com/press-releases/galapagos-expands-and-extends-drug-discovery-collaboration-with-amgen-into-2008/ 2023-12-10T21:54:43+00:00 https://lakefrontbio.com/press-releases/galapagos-en-amgen-breiden-samenwerking-uit-naar-eind-2008/ 2023-12-10T21:54:43+00:00 https://lakefrontbio.com/press-releases/galapagos-acquires-proskelia-from-prostrakan-and-raises-e31-million/ 2023-12-10T21:54:43+00:00 https://lakefrontbio.com/press-releases/galapagos-neemt-proskelia-over-van-prostrakan-en-plaatst-e31-miljoen-bij-institutionele-beleggers/ 2023-12-10T21:54:44+00:00 https://lakefrontbio.com/press-releases/galapagos-and-the-als-association-announce-e2-4-million-target-discovery-alliance/ 2023-12-10T21:54:44+00:00 https://lakefrontbio.com/press-releases/galapagos-en-als-association-kondigen-e2-4-miljoen-target-discovery-alliantie-aan/ 2023-12-10T21:54:44+00:00 https://lakefrontbio.com/press-releases/galapagos-to-acquire-inpharmatica/ 2023-12-10T21:54:44+00:00 https://lakefrontbio.com/press-releases/galapagos-neemt-inpharmatica-over/ 2023-12-10T21:54:45+00:00 https://lakefrontbio.com/press-releases/galapagos-awarded-european-union-grant/ 2023-12-10T21:54:45+00:00 https://lakefrontbio.com/press-releases/galapagos-krijgt-subsidie-van-europese-unie/ 2023-12-10T21:54:45+00:00 https://lakefrontbio.com/press-releases/biofocus-dpi-leiden-verkrijgt-iso-certificering/ 2023-12-10T21:54:46+00:00 https://lakefrontbio.com/press-releases/biofocus-dpi-extends-iso-certification-to-leiden-operations/ 2023-12-10T21:54:46+00:00 https://lakefrontbio.com/press-releases/galapagos-extends-target-discovery-alliance-with-cystic-fibrosis-foundation-therapeutics/ 2023-12-10T21:54:46+00:00 https://lakefrontbio.com/press-releases/galapagos-en-cystic-fibrosis-foundation-breiden-alliantie-in-taaislijmziekte-uit/ 2023-12-10T21:54:46+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-samenwerken-met-leo-pharma-in-antibacterieel-onderzoek/ 2023-12-10T21:54:47+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-natural-compounds-collaboration-with-leo-pharma/ 2023-12-10T21:54:47+00:00 https://lakefrontbio.com/press-releases/galapagos-haalt-e111-miljoen-op-door-uitgifte-van-nieuwe-aandelen/ 2023-12-10T21:54:47+00:00 https://lakefrontbio.com/press-releases/galapagos-raises-e11-1-million-from-new-equity-issue/ 2023-12-10T21:54:48+00:00 https://lakefrontbio.com/press-releases/galapagos-and-oneworld-health-collaborate-to-develop-new-drugs-for-the-treatment-of-diarrheal-diseases/ 2023-12-10T21:54:48+00:00 https://lakefrontbio.com/press-releases/galapagos-en-oneworld-health-gaan-geneesmiddelen-tegen-diarreeziekten-ontwikkelen/ 2023-12-10T21:54:48+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-sharp-revenue-increase-and-profitability-of-service-division-in-its-half-year-2006-results/ 2023-12-10T21:54:49+00:00 https://lakefrontbio.com/press-releases/galapagos-maakt-sterke-omzetstijging-en-winstgevendheid-van-service-divisie-bekend-in-haar-halfjaarcijfers-2006/ 2023-12-10T21:54:49+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-new-collaboration-with-astrazeneca/ 2023-12-10T21:54:49+00:00 https://lakefrontbio.com/press-releases/galapagos-start-nieuw-samenwerkingsverband-met-astrazeneca/ 2023-12-10T21:54:49+00:00 https://lakefrontbio.com/press-releases/galapagos-krijgt-e18-miljoen-subsidie-toegekend-voor-nieuwe-methoden-in-geneesmiddelenontwikkeling/ 2023-12-10T21:54:50+00:00 https://lakefrontbio.com/press-releases/galapagos-awarded-e1-8-million-grant-to-accelerate-drug-discovery/ 2023-12-10T21:54:50+00:00 https://lakefrontbio.com/press-releases/galapagos-en-cellzome-werken-samen-in-kinase-drug-discovery/ 2023-12-10T21:54:50+00:00 https://lakefrontbio.com/press-releases/galapagos-and-cellzome-in-kinase-drug-discovery-collaboration/ 2023-12-10T21:54:50+00:00 https://lakefrontbio.com/press-releases/galapagos-overname-van-dpi-activiteiten-afgerond/ 2023-12-10T21:54:51+00:00 https://lakefrontbio.com/press-releases/galapagos-completes-acquisition-of-drug-discovery-service-operations-of-discovery-partners-international/ 2023-12-10T21:54:51+00:00 https://lakefrontbio.com/press-releases/galapagos-expands-chemistry-services-through-contracts-with-indian-companies/ 2023-12-10T21:54:51+00:00 https://lakefrontbio.com/press-releases/galapagos-breidt-haar-chemie-services-uit-middels-contracten-met-bedrijven-in-india/ 2023-12-10T21:54:52+00:00 https://lakefrontbio.com/press-releases/galapagos-expands-chemistry-services-through-contracts-with-indian-companies-2/ 2023-12-10T21:54:52+00:00 https://lakefrontbio.com/press-releases/galapagos-nv-galapagos-or-company-annual-report-and-accounts/ 2023-12-10T21:54:52+00:00 https://lakefrontbio.com/press-releases/sadsadas/ 2023-12-10T21:54:52+00:00 https://lakefrontbio.com/press-releases/galapagos-to-acquire-drug-discovery-service-operations-of-discovery-partners-international/ 2023-12-10T21:54:52+00:00 https://lakefrontbio.com/press-releases/galapagos-neemt-drug-discovery-activiteiten-over-van-discovery-partners-international/ 2023-12-10T21:54:53+00:00 https://lakefrontbio.com/press-releases/galapagos-to-acquire-drug-discovery-service-operations-of-discovery-partners-international-2/ 2023-12-10T21:54:53+00:00 https://lakefrontbio.com/press-releases/glaxosmithkline-en-galapagos-gaan-een-langdurige-alliantie-aan-voor-de-ontwikkeling-van-een-geneesmiddel-voor-artrose/ 2023-12-10T21:54:53+00:00 https://lakefrontbio.com/press-releases/glaxosmithkline-and-galapagos-enter-into-drug-discovery-and-development-alliance-in-osteoarthritis/ 2023-12-10T21:54:54+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-exclusive-agreement-with-upstate-for-marketing-and-sales-of-adenovirus-products/ 2023-12-10T21:54:54+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-een-exclusieve-overeenkomst-aan-met-upstate-voor-het-aanbieden-en-verkopen-van-haar-adenovirale-producten/ 2023-12-10T21:54:54+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-exclusive-agreement-with-upstate-for-marketing-and-sales-of-adenovirus-products-2/ 2023-12-10T21:54:54+00:00 https://lakefrontbio.com/press-releases/galapagos-creates-new-warrant-plan-14/ 2023-12-10T21:54:55+00:00 https://lakefrontbio.com/press-releases/galapagos-creates-new-warrant-plan-15/ 2023-12-10T21:54:55+00:00 https://lakefrontbio.com/press-releases/galapagos-creeert-nieuw-warrantplan-15/ 2023-12-10T21:54:55+00:00 https://lakefrontbio.com/press-releases/galapagos-en-arthrogen-gaan-samenwerkingsverband-aan-in-target-discovery/ 2023-12-10T21:54:55+00:00 https://lakefrontbio.com/press-releases/galapagos-and-arthrogen-enter-target-discovery/ 2023-12-10T21:55:08+00:00 https://lakefrontbio.com/press-releases/galapagos-and-arthrogen-enter-target-discovery-alliance/ 2023-12-10T21:55:08+00:00 https://lakefrontbio.com/press-releases/galapagos-enters-a-three-year-collaboration-with-roche/ 2023-12-10T21:55:09+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-driejarige-samenwerking-met-roche-aan/ 2023-12-10T21:55:09+00:00 https://lakefrontbio.com/press-releases/galapagos-enters-a-three-year-collaboration-with-roche-2/ 2023-12-10T21:55:09+00:00 https://lakefrontbio.com/press-releases/notice-of-agm/ 2023-12-10T21:55:09+00:00 https://lakefrontbio.com/press-releases/galapagos-maakt-resultaten-2005-bekend/ 2023-12-10T21:55:10+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-2005-annual-results/ 2023-12-10T21:55:10+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-2005-annual-results-2/ 2023-12-10T21:55:10+00:00 https://lakefrontbio.com/press-releases/galapagos-creates-new-warrant-plan-16/ 2023-12-10T21:55:10+00:00 https://lakefrontbio.com/press-releases/galapagos-creeert-nieuw-warrantplan-16/ 2023-12-10T21:55:11+00:00 https://lakefrontbio.com/press-releases/galapagos-creates-new-warrant-plan-17/ 2023-12-10T21:55:11+00:00 https://lakefrontbio.com/press-releases/galapagos-and-basf-extend-research-collaborations/ 2023-12-10T21:55:11+00:00 https://lakefrontbio.com/press-releases/galapagos-and-basf-extend-research-collaborations-2/ 2023-12-10T21:55:12+00:00 https://lakefrontbio.com/press-releases/galapagos-en-basf-breiden-onderzoeks-samenwerking-uit/ 2023-12-10T21:55:12+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-samenwerking-aan-met-cancer-research-technology-voor-de-ontwikkeling-van-antikanker-geneesmiddelen/ 2023-12-10T21:55:12+00:00 https://lakefrontbio.com/press-releases/galapagos-and-cancer-research-technology-announce-new-anti-cancer-drug-discovery-collaboration/ 2023-12-10T21:55:12+00:00 https://lakefrontbio.com/press-releases/galapagos-and-cancer-research-technology-announce-new-anti-cancer-drug-discovery-collaboration-2/ 2023-12-10T21:55:13+00:00 https://lakefrontbio.com/press-releases/galapagos-expects-4q-05-revenues-to-meet-guidance-reduced-full-year-2005-cash-burn/ 2023-12-10T21:55:13+00:00 https://lakefrontbio.com/press-releases/galapagos-expects-4q-05-revenues-to-meet-guidance-reduced-full-year-2005-cash-burn-2/ 2023-12-10T21:55:13+00:00 https://lakefrontbio.com/press-releases/galapagos-verwacht-4q-05-opbrengsten-overeenkomstig-richtlijn-verminderde-cash-burn-in-het-jaar-2005/ 2023-12-10T21:55:14+00:00 https://lakefrontbio.com/press-releases/galapagos-enters-new-collaboration-in-autoimmune-discovery-research/ 2023-12-10T21:55:14+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-nieuwe-samenwerking-aan-in-auto-immuunziekten/ 2023-12-10T21:55:14+00:00 https://lakefrontbio.com/press-releases/galapagos-enters-new-collaboration-in-autoimmune-discovery-research-2/ 2023-12-10T21:55:15+00:00 https://lakefrontbio.com/press-releases/aanstelling-angus-macleod-als-director-medicinal-chemistry/ 2023-12-10T21:55:15+00:00 https://lakefrontbio.com/press-releases/angus-macleod-named-director-of-medicinal-chemistry-at-biofocus/ 2023-12-10T21:55:15+00:00 https://lakefrontbio.com/press-releases/additional-listing-5/ 2023-12-10T21:55:15+00:00 https://lakefrontbio.com/press-releases/galapagos-en-prolysis-breiden-onderzoekssamenwerking-naar-nieuwe-antibiotica-uit/ 2023-12-10T21:55:15+00:00 https://lakefrontbio.com/press-releases/galapagos-and-prolysis-extend-research-collaboration/ 2023-12-10T21:55:16+00:00 https://lakefrontbio.com/press-releases/galapagos-and-prolysis-extend-research-collaboration-2/ 2023-12-10T21:55:16+00:00 https://lakefrontbio.com/press-releases/biofocus-kondigt-samenwerking-aan-met-cresset-voor-de-ontwikkeling-van-nieuwe-chemische-molecuulcollecties/ 2023-12-10T21:55:16+00:00 https://lakefrontbio.com/press-releases/biofocus-collaborates-with-cresset-to-develop-new-range-of-compound-libraries/ 2023-12-10T21:55:16+00:00 https://lakefrontbio.com/press-releases/galapagos-extends-its-collaboration-with-amgen-throughout-2006/ 2023-12-10T21:55:17+00:00 https://lakefrontbio.com/press-releases/galapagos-extends-its-collaboration-with-amgen-throughout-2006-2/ 2023-12-10T21:55:17+00:00 https://lakefrontbio.com/press-releases/galapagos-bouwt-samenwerking-met-amgen-uit-in-2006/ 2023-12-10T21:55:17+00:00 https://lakefrontbio.com/press-releases/additional-listing-6/ 2023-12-10T21:55:17+00:00 https://lakefrontbio.com/press-releases/re-contract/ 2023-12-10T21:55:17+00:00 https://lakefrontbio.com/press-releases/senexis-and-biofocus-collaborate-to-select-development-candidates-for-senexis-alzheimers-disease-targets/ 2023-12-10T21:55:18+00:00 https://lakefrontbio.com/press-releases/senexis-en-biofocus-werken-samen-om-kandidaat-medicijnen-te-ontwikkelen-voor-senexis-targets-voor-de-ziekte-van-alzheimer/ 2023-12-10T21:55:18+00:00 https://lakefrontbio.com/press-releases/convocation-of-egm/ 2023-12-10T21:55:18+00:00 https://lakefrontbio.com/press-releases/galapagos-enters-into-discovery-collaboration-with-idenix-for-infectious-disease-programs/ 2023-12-10T21:55:18+00:00 https://lakefrontbio.com/press-releases/galapagos-sluit-samenwerkingsovereenkomst-met-idenix-op-gebied-van-infectieziekten/ 2023-12-10T21:55:19+00:00 https://lakefrontbio.com/press-releases/galapagos-enters-into-discovery-collaboration-with-idenix-for-infectious-disease-programs-2/ 2023-12-10T21:55:19+00:00 https://lakefrontbio.com/press-releases/galapagos-rapporteert-derde-kwartaalcijfers-2005/ 2023-12-10T21:55:19+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-third-quarter-2005-results/ 2023-12-10T21:55:19+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-third-quarter-2005-results-2/ 2023-12-10T21:55:20+00:00 https://lakefrontbio.com/press-releases/galapagos-appoints-david-smith-as-chief-financial-officer/ 2023-12-10T21:55:20+00:00 https://lakefrontbio.com/press-releases/galapagos-appoints-david-smith-as-chief-financial-officer-2/ 2023-12-10T21:55:20+00:00 https://lakefrontbio.com/press-releases/galapagos-benoemt-david-smith-als-financieel-directeur/ 2023-12-10T21:55:20+00:00 https://lakefrontbio.com/press-releases/galapagos-to-release-third-quarter-results-on-10-november-2005/ 2023-12-10T21:55:21+00:00 https://lakefrontbio.com/press-releases/galapagos-exceeds-92-acceptance-of-biofocus-shares-and-closes-offer/ 2023-12-10T21:55:34+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-meer-dan-92-van-de-biofocus-aandelen-en-sluit-de-bieding/ 2023-12-10T21:55:34+00:00 https://lakefrontbio.com/press-releases/galapagos-bouwt-samenwerking-met-serono-uit/ 2023-12-10T21:55:34+00:00 https://lakefrontbio.com/press-releases/galapagos-expands-its-collaboration-with-serono/ 2023-12-10T21:55:35+00:00 https://lakefrontbio.com/press-releases/galapagos-featured-in-leading-drug-discovery-journal/ 2023-12-10T21:55:35+00:00 https://lakefrontbio.com/press-releases/galapagos-publiceert-in-vooraanstaand-tijdschrift-voor-geneesmiddelenonderzoek/ 2023-12-10T21:55:35+00:00 https://lakefrontbio.com/press-releases/galapagos-declares-the-offer-for-biofocus-unconditional-as-to-acceptances/ 2023-12-10T21:55:35+00:00 https://lakefrontbio.com/press-releases/galapagos-verklaart-het-bod-op-biofocus-gestand-te-doen-voor-de-aangemelde-aandelen/ 2023-12-10T21:55:35+00:00 https://lakefrontbio.com/press-releases/recommended-offer-for-biofocus-plc-declared-unconditional-as-to-acceptances/ 2023-12-10T21:55:36+00:00 https://lakefrontbio.com/press-releases/aanbevolen-bieding-op-biofocus-plc-gestand-gedaan-voor-wat-betreft-aanmeldingen/ 2023-12-10T21:55:36+00:00 https://lakefrontbio.com/press-releases/galapagos-obtains-u-s-patent-protecting-its-discovery-platform/ 2023-12-10T21:55:36+00:00 https://lakefrontbio.com/press-releases/galapagos-verkrijgt-octrooibescherming-voor-haar-technologie-platform-in-de-vs/ 2023-12-10T21:55:36+00:00 https://lakefrontbio.com/press-releases/galapagos-to-webcast-analyst-day-on-friday-october-7-2005/ 2023-12-10T21:55:37+00:00 https://lakefrontbio.com/press-releases/recommended-offer-by-galapagos-nv-for-biofocus-plc/ 2023-12-10T21:55:37+00:00 https://lakefrontbio.com/press-releases/galapagos-wil-biofocus-overnemen-via-een-aanbevolen-bieding-op-alle-aandelen-biofocus/ 2023-12-10T21:55:37+00:00 https://lakefrontbio.com/press-releases/galapagos-amsterdam-molecular-therapeutics-netherlands-institute-for-brain-research-en-vrije-universiteit-amsterdam-samen-in-ontwikkeling-van-innovatieve-behandelingsmethoden-tegen-traumatische-rugg/ 2023-12-10T21:55:37+00:00 https://lakefrontbio.com/press-releases/galapagos-amsterdam-molecular-therapeutics-netherlands-institute-for-brain-research-and-vrije-universiteit-amsterdam-announce-collaboration-to-develop-innovative-treatments-for-traumatic-spinal-cor/ 2023-12-10T21:55:38+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-half-year-2005-results/ 2023-12-10T21:55:38+00:00 https://lakefrontbio.com/press-releases/galapagos-rapporteert-halfjaarcijfers-2005/ 2023-12-10T21:55:38+00:00 https://lakefrontbio.com/press-releases/galapagos-en-high-q-foundation-kondigen-principe-akkoord-aan-over-e-24-miljoen-alliantie-ter-identificatie-van-geneesmiddelentargets-voor-de-ziekte-van-huntington/ 2023-12-10T21:55:38+00:00 https://lakefrontbio.com/press-releases/galapagos-and-high-q-foundation-announce-in-principle-agreement-on-e2-4-million-alliance-to-discover-drug-targets-for-huntington-disease/ 2023-12-10T21:55:39+00:00 https://lakefrontbio.com/press-releases/galapagos-nv-zobio-bv-pyxis-discovery-bv-and-leiden-university-collaborate-in-arthritis-drug-discovery-program/ 2023-12-10T21:55:39+00:00 https://lakefrontbio.com/press-releases/galapagos-zobio-pyxis-discovery-en-de-universiteit-leiden-gaan-samenwerken-in-de-ontwikkeling-van-artritis-geneesmiddelen/ 2023-12-10T21:55:39+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-first-half-2005-results/ 2023-12-10T21:55:40+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-first-half-2005-results-2/ 2023-12-10T21:55:40+00:00 https://lakefrontbio.com/press-releases/galapagos-to-release-half-year-results-on-friday-august-12/ 2023-12-10T21:55:40+00:00 https://lakefrontbio.com/press-releases/galapagos-sluit-overeenkomst-voor-research-samenwerking/ 2023-12-10T21:55:40+00:00 https://lakefrontbio.com/press-releases/galapagos-signs-research-collaboration-agreement/ 2023-12-10T21:55:40+00:00 https://lakefrontbio.com/press-releases/galapagos-and-celera-genomics-sign-gene-function-analysis-agreement/ 2023-12-10T21:55:41+00:00 https://lakefrontbio.com/press-releases/galapagos-tekent-overeenkomst-met-celera-genomics-voor-gen-funktie-analyse/ 2023-12-10T21:55:41+00:00 https://lakefrontbio.com/press-releases/galapagos-haalt-additioneel-e-20-miljoen-op-bij-beursgang/ 2023-12-10T21:55:41+00:00 https://lakefrontbio.com/press-releases/galapagos-raises-additional-e-2-0-million-in-ipo/ 2023-12-10T21:55:41+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-changes-to-board-of-directors/ 2023-12-10T21:55:42+00:00 https://lakefrontbio.com/press-releases/galapagos-wijzigt-samenstelling-board-of-directors/ 2023-12-10T21:55:42+00:00 https://lakefrontbio.com/press-releases/galapagos-nv-asinex-ltd-initiate-drug-discovery-collaboration-in-bone-and-joint-diseases/ 2023-12-10T21:55:42+00:00 https://lakefrontbio.com/press-releases/galapagos-nv-en-asinex-ltd-gaan-een-drug-discovery-samenwerking-aan-in-bot-en-gewrichtsziekten/ 2023-12-10T21:55:42+00:00 https://lakefrontbio.com/press-releases/galapagos-haalt-e-20-miljoen-op-bij-beursgang-euronext-brussel-en-euronext-amsterdam/ 2023-12-10T21:55:42+00:00 https://lakefrontbio.com/press-releases/galapagos-raises-e-20-million-with-ipo-on-euronext-brussels-and-euronext-amsterdam/ 2023-12-10T21:55:43+00:00 https://lakefrontbio.com/press-releases/galapagos-extends-subscription-period-for-shares-galapagos/ 2023-12-10T21:55:43+00:00 https://lakefrontbio.com/press-releases/galapagos-extends-subscription-period-for-shares-galapagos-2/ 2023-12-10T21:55:43+00:00 https://lakefrontbio.com/press-releases/galapagos-verlengt-inschrijving-op-aandelen-galapagos/ 2023-12-10T21:55:44+00:00 https://lakefrontbio.com/press-releases/galapagos-verlengt-inschrijving-op-aandelen-galapagos-2/ 2023-12-10T21:55:44+00:00 https://lakefrontbio.com/press-releases/cnbc-interview-with-galapagos-ceo-onno-van-de-stolpe/ 2023-12-10T21:55:44+00:00 https://lakefrontbio.com/press-releases/cystic-fibrosis-foundation-therapeutics-and-galapagos-initiate-galapagos-initiate-alliance-to-discover-drug-targets/ 2023-12-10T21:55:44+00:00 https://lakefrontbio.com/press-releases/galapagos-appoints-andre-hoekema-as-managing-director-galadeno/ 2023-12-10T21:55:44+00:00 https://lakefrontbio.com/press-releases/staf-van-reet-to-lead-galapagos-corporate-development/ 2023-12-10T21:55:45+00:00 https://lakefrontbio.com/press-releases/tno-and-galapagos-enter-into-drug-target-characterization-collaboration/ 2023-12-10T21:55:45+00:00 https://lakefrontbio.com/press-releases/galapagos-is-considering-a-stock-exchange-listing/ 2023-12-10T21:55:45+00:00 https://lakefrontbio.com/press-releases/galapagos-is-considering-a-stock-exchange-listing-2/ 2023-12-10T21:55:45+00:00 https://lakefrontbio.com/press-releases/boehringer-ingelheim-licenses-results-from-target-discovery-collaboration-with-galapagos/ 2023-12-10T21:55:45+00:00 https://lakefrontbio.com/press-releases/glaxosmithkline-forms-target-discovery-alliance-in-asthma-with-galapagos/ 2023-12-10T21:56:01+00:00 https://lakefrontbio.com/press-releases/graham-dixon-joins-galapagos-as-chief-scientific-officer/ 2023-12-10T21:56:01+00:00 https://lakefrontbio.com/press-releases/celgene-and-galapagos-enter-target-discovery-collaboration/ 2023-12-10T21:56:01+00:00 https://lakefrontbio.com/press-releases/wyeth-selects-novel-drug-targets-in-osteoporosis-collaboration-with-galapagos/ 2023-12-10T21:56:02+00:00 https://lakefrontbio.com/press-releases/galapagos-appoints-raj-parekh-as-chairman-and-wilson-totten-to-board-of-directors/ 2023-12-10T21:56:02+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-the-separation-of-its-drug-discovery-and-target-discovery-service-forms-galadenotm-as-an-independent-business-unit/ 2023-12-10T21:56:02+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-success-in-identification-and-validation-of-proprietary-drug-targets-and-moves-into-drug-discovery/ 2023-12-10T21:56:02+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-grant-for-alzheimers-disease-research/ 2023-12-10T21:56:03+00:00 https://lakefrontbio.com/press-releases/bayer-healthcare-and-galapagos-in-target-discovery-collaboration/ 2023-12-10T21:56:03+00:00 https://lakefrontbio.com/press-releases/wyeth-pharmaceuticals-and-galapagos-form-discovery-alliance-in-osteoporosis/ 2023-12-10T21:56:03+00:00 https://lakefrontbio.com/press-releases/boehringer-ingelheim-and-galapagos-genomics-team-up-in-antiviral-discovery-research-program/ 2023-12-10T21:56:03+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-adenoviral-sirna-based-results/ 2023-12-10T21:56:04+00:00 https://lakefrontbio.com/press-releases/galapagos-genomics-and-procter-gamble-collaborate-in-osteoporosis/ 2023-12-10T21:56:04+00:00 https://lakefrontbio.com/press-releases/galapagos-genomics-to-launchfull-length-human-gene-adenoviral-expression-library/ 2023-12-10T21:56:04+00:00 https://lakefrontbio.com/press-releases/inpharmatica-and-galapagos-genomics-enter-drug-discovery-collaboration/ 2023-12-10T21:56:05+00:00 https://lakefrontbio.com/press-releases/galapagos-genomics-and-degussa-enter-into-nutraceutical-research-agreement/ 2023-12-10T21:56:05+00:00 https://lakefrontbio.com/press-releases/galapagos-launches-gene-silencing-platform-at-keystone-symposia/ 2023-12-10T21:56:05+00:00 https://lakefrontbio.com/press-releases/galapagos-genomics-receives-grants-to-expand-functional-genomics-platform/ 2023-12-10T21:56:05+00:00 https://lakefrontbio.com/press-releases/robin-brown-joins-galapagos-genomics-as-chief-scientific-officer/ 2023-12-10T21:56:06+00:00 https://lakefrontbio.com/press-releases/galapagos-genomics-raises-euro21-4-million-in-private-placement/ 2023-12-10T21:56:06+00:00 https://lakefrontbio.com/press-releases/galapagos-genomics-and-exelixis-collaborate-in-gene-function-analysis/ 2023-12-10T21:56:06+00:00 https://lakefrontbio.com/press-releases/galapagos-genomics-receives-us-patent-for-its-phenoselecttm-platform/ 2023-12-10T21:56:07+00:00 https://lakefrontbio.com/press-releases/galapagos-genomics-and-euroscreen-enter-into-a-collaboration-on-g-protein-coupled-receptors/ 2023-12-10T21:56:07+00:00 https://lakefrontbio.com/press-releases/jyseleca-filgotinib-approved-in-the-european-union-for-the-treatment-of-ulcerative-colitis/ 2023-12-12T13:43:55+00:00 https://lakefrontbio.com/press-releases/jyseleca-filgotinib-licensed-for-the-treatment-of-adult-patients-with-moderately-to-severely-active-ulcerative-colitis-in-great-britain/ 2023-12-12T13:52:47+00:00 https://lakefrontbio.com/press-releases/jyseleca-filgotinib-krijgt-vergunning-voor-de-behandeling-van-volwassen-patienten-met-matige-tot-ernstige-actieve-colitis-ulcerosa-in-groot-brittannie/ 2023-12-12T13:53:06+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-transparency-notification-from-fmr-llc/ 2023-12-15T22:02:22+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-transparantieverklaring-van-fmr-llc/ 2023-12-15T22:02:22+00:00 https://lakefrontbio.com/press-releases/galapagos-presented-encouraging-initial-safety-and-efficacy-data-at-2023-ebmt-eha-for-point-of-care-manufactured-car-t-candidate-glpg5201-in-rrcll/ 2023-12-20T22:02:29+00:00 https://lakefrontbio.com/press-releases/galapagos-heeft-bemoedigende-eerste-gegevens-gepresenteerd-over-veiligheid-en-werkzaamheid-van-point-of-care-vervaardigde-car-t-kandidaat-glpg5201-in-rrcll-op-ebmt-eha-2023/ 2023-12-20T22:02:30+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-topline-results-from-phase-3-diversity-trial-of-filgotinib-in-crohns-disease/ 2023-12-20T22:02:30+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-topline-resultaten-aan-van-fase-3-diversity-studie-met-filgotinib-bij-de-ziekte-van-crohn/ 2023-12-20T22:02:31+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-third-quarter-2023-results-and-releases-new-encouraging-data-from-car-t-studies-for-presentation-at-ash-2023/ 2024-01-04T09:16:50+00:00 https://lakefrontbio.com/press-releases/galapagos-rapporteert-derde-kwartaal-2023-resultaten-en-deelt-nieuwe-bemoedigende-data-van-car-t-studies-die-op-ash-2023-gepresenteerd-worden/ 2024-01-04T09:16:51+00:00 https://lakefrontbio.com/press-releases/galapagos-appoints-simon-sturge-to-its-board-of-directors/ 2024-01-04T09:16:52+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-de-start-aan-van-een-fase-2-studie-met-de-selectieve-tyk2-remmer-glpg3667-bij-patienten-met-actieve-systemische-lupus-erythematodes/ 2024-01-04T09:16:53+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-start-of-phase-2-study-with-selective-tyk2-inhibitor-glpg3667-in-patients-with-active-systemic-lupus-erythematosus/ 2024-01-04T09:16:53+00:00 https://lakefrontbio.com/press-releases/galapagos-rapporteert-financiele-resultaten-over-het-eerste-halfjaar-van-2023/ 2024-01-04T09:16:54+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-first-half-year-2023-financial-results/ 2024-01-04T09:16:54+00:00 https://lakefrontbio.com/press-releases/galapagos-benoemt-thad-huston-tot-chief-financial-officer-en-chief-operating-officer/ 2024-01-04T09:16:56+00:00 https://lakefrontbio.com/press-releases/galapagos-appoints-dr-susanne-schaffert-as-non-executive-independent-director-to-its-board/ 2024-01-04T09:16:56+00:00 https://lakefrontbio.com/press-releases/galapagos-appoints-thad-huston-as-chief-financial-officer-and-chief-operating-officer/ 2024-01-04T09:16:56+00:00 https://lakefrontbio.com/press-releases/galapagos-benoemt-dr-susanne-schaffert-tot-niet-uitvoerend-onafhankelijk-lid-van-de-raad-van-bestuur/ 2024-01-04T09:16:57+00:00 https://lakefrontbio.com/press-releases/galapagos-to-showcase-car-t-point-of-care-manufacturing-and-initial-phase-1-2-cll-data-with-cd19-car-t-candidate-glpg5201-at-the-eha-2023-congress/ 2024-01-04T09:16:57+00:00 https://lakefrontbio.com/press-releases/galapagos-toont-car-t-point-of-care-productie-en-eerste-fase-1-2-cll-data-met-cd19-car-t-kandidaat-glpg5201-op-het-eha-2023-congres/ 2024-01-04T09:16:57+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-start-aan-van-fase-2-studie-met-selectieve-tyk2-remmer-glpg3667-in-patienten-met-dermatomyositis/ 2024-01-04T09:16:58+00:00 https://lakefrontbio.com/press-releases/galapagos-demonstrates-commitment-to-immunology-with-new-data-in-rheumatoid-arthritis-at-eular-2023/ 2024-01-04T09:16:58+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-start-of-phase-2-study-with-selective-tyk2-inhibitor-glpg3667-in-patients-with-dermatomyositis/ 2024-01-04T09:16:58+00:00 https://lakefrontbio.com/press-releases/galapagos-creates-new-subscription-right-plans/ 2024-01-04T09:16:59+00:00 https://lakefrontbio.com/press-releases/galapagos-toont-toewijding-in-immunologie-met-nieuwe-data-in-reumatoide-artritis-tijdens-eular-2023/ 2024-01-04T09:16:59+00:00 https://lakefrontbio.com/press-releases/galapagos-rapporteert-financiele-resultaten-voor-het-eerste-kwartaal-van-2023/ 2024-01-04T09:17:00+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-first-quarter-2023-financial-results/ 2024-01-04T09:17:00+00:00 https://lakefrontbio.com/press-releases/galapagos-creeert-nieuwe-inschrijvingsrechtenplannen/ 2024-01-04T09:17:00+00:00 https://lakefrontbio.com/press-releases/galapagos-initiates-phase-3-program-with-filgotinib-in-patients-with-active-axial-spondyloarthritis/ 2024-01-04T09:17:01+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-vertrek-aan-van-bart-filius-chief-operating-officer-en-chief-financial-officer/ 2024-01-04T09:17:01+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-departure-of-bart-filius-chief-operating-officer-and-chief-financial-officer/ 2024-01-04T09:17:01+00:00 https://lakefrontbio.com/press-releases/galapagos-start-fase-3-programma-met-filgotinib-bij-patienten-met-actieve-axiale-spondyloartritis/ 2024-01-04T09:17:02+00:00 https://lakefrontbio.com/press-releases/galapagos-shareholders-approve-all-resolutions-proposed-by-the-board-of-directors-at-the-annual-shareholders-meeting/ 2024-01-04T09:17:02+00:00 https://lakefrontbio.com/press-releases/galapagos-aandeelhouders-keuren-alle-door-de-raad-van-bestuur-voorgestelde-besluiten-goed-op-de-jaarlijkse-aandeelhoudersvergadering/ 2024-01-04T09:17:02+00:00 https://lakefrontbio.com/press-releases/galapagos-and-novalix-enter-into-an-integrated-drug-discovery-collaboration/ 2024-01-04T09:17:03+00:00 https://lakefrontbio.com/press-releases/galapagos-en-novalix-gaan-een-geintegreerde-samenwerking-aan-op-het-gebied-van-geneesmiddelenonderzoek/ 2024-01-04T09:17:04+00:00 https://lakefrontbio.com/press-releases/galapagos-publishes-2022-annual-report-and-announces-annual-shareholders-meeting/ 2024-01-04T09:17:04+00:00 https://lakefrontbio.com/press-releases/galapagos-publiceert-jaarverslag-2022-en-kondigt-gewone-algemene-vergadering-aan/ 2024-01-04T09:17:04+00:00 https://lakefrontbio.com/press-releases/galapagos-increases-share-capital-through-subscription-right-exercises/ 2024-01-04T09:17:05+00:00 https://lakefrontbio.com/press-releases/galapagos-verhoogt-kapitaal-door-uitoefening-van-inschrijvingsrechten/ 2024-01-04T09:17:05+00:00 https://lakefrontbio.com/press-releases/galapagos-to-present-new-data-from-long-term-extension-study-of-filgotinib-in-ulcerative-colitis-at-annual-ecco-congress-2023/ 2024-01-04T09:17:05+00:00 https://lakefrontbio.com/press-releases/galapagos-presenteert-nieuwe-data-van-langetermijn-uitbreidingsstudie-van-filgotinib-bij-colitis-ulcerosa-op-jaarlijks-ecco-congres-2023/ 2024-01-04T09:17:06+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-full-year-2022-results-and-outlook-for-2023/ 2024-01-04T09:17:06+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-2022-jaarresultaten-en-vooruitzichten-2023-aan/ 2024-01-04T09:17:07+00:00 https://lakefrontbio.com/press-releases/galapagos-to-host-kol-event-on-december-10-2023-at-1100-am-pst-to-discuss-new-data-presented-at-ash-2023/ 2024-01-04T21:00:07+00:00 https://lakefrontbio.com/press-releases/galapagos-organiseert-een-kol-evenement-op-10-december-2023-om-1100-am-pst-om-nieuwe-gegevens-te-bespreken-die-zijn-gepresenteerd-op-ash-2023/ 2024-01-04T21:00:07+00:00 https://lakefrontbio.com/press-releases/galapagos-presents-new-encouraging-data-at-ash-2023-from-ongoing-cd19-car-t-studies-with-glpg5201-and-glpg5101/ 2024-01-30T23:02:06+00:00 https://lakefrontbio.com/press-releases/galapagos-presenteert-nieuwe-bemoedigende-resultaten-op-ash-2023-voor-lopende-cd19-car-t-studies-met-glpg5201-en-glpg5101/ 2024-01-30T23:02:06+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-start-of-papilio-1-phase-1-2-multiple-myeloma-study-of-point-of-care-manufactured-bcma-car-t-candidate-glpg5301/ 2024-02-15T21:02:23+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-start-aan-van-papilio-1-fase-1-2-multipel-myeloom-studie-met-point-of-care-vervaardigde-bcma-car-t-kandidaat-glpg5301/ 2024-02-15T21:02:24+00:00 https://lakefrontbio.com/press-releases/galapagos-establishes-strategic-collaboration-with-bridgene-biosciences-to-expand-small-molecule-drug-discovery-in-oncology/ 2024-03-26T20:03:56+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-een-strategische-samenwerking-aan-met-bridgene-biosciences-om-de-ontdekking-van-kleine-moleculegeneesmiddelen-in-oncologie-uit-te-breiden/ 2024-03-26T20:03:56+00:00 https://lakefrontbio.com/press-releases/galapagos-benoemt-simon-sturge-tot-lid-van-haar-raad-van-bestuur/ 2024-03-26T20:40:57+00:00 https://lakefrontbio.com/press-releases/galapagos-enters-into-strategic-collaboration-agreement-with-thermo-fisher-scientific-to-further-expand-its-decentralized-car-t-manufacturing-network-in-the-u-s/ 2024-03-27T23:02:05+00:00 https://lakefrontbio.com/press-releases/galapagos-gaat-strategische-samenwerkingsovereenkomst-aan-met-thermo-fisher-scientific-om-gedecentraliseerd-car-t-productienetwerk-in-de-vs-verder-uit-te-breiden/ 2024-03-27T23:02:06+00:00 https://lakefrontbio.com/press-releases/galapagos-presents-at-ebmt-eha-annual-meeting-2024/ 2024-04-30T20:02:29+00:00 https://lakefrontbio.com/press-releases/galapagos-presenteert-op-de-jaarlijkse-ebmt-eha-meeting-van-2024/ 2024-04-30T20:02:29+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-full-year-2023-results-and-outlook-for-2024/ 2024-05-02T20:01:57+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-2023-jaarresultaten-en-vooruitzichten-2024-aan/ 2024-05-02T20:01:57+00:00 https://lakefrontbio.com/press-releases/galapagos-appoints-andrew-dickinson-as-non-executive-non-independent-director-to-its-board/ 2024-05-14T22:02:07+00:00 https://lakefrontbio.com/press-releases/galapagos-benoemt-andrew-dickinson-tot-niet-uitvoerend-niet-onafhankelijk-bestuurder-van-haar-raad-van-bestuur/ 2024-05-14T22:02:07+00:00 https://lakefrontbio.com/press-releases/galapagos-publishes-2023-annual-report-and-announces-annual-and-extraordinary-shareholders-meetings/ 2024-05-16T20:02:21+00:00 https://lakefrontbio.com/press-releases/galapagos-publiceert-2023-jaarverslag-en-kondigt-jaarlijkse-gewone-algemene-en-buitengewone-algemene-aandeelhoudersvergaderingen-aan/ 2024-05-16T20:02:21+00:00 https://lakefrontbio.com/press-releases/galapagos-showcases-innovative-approach-in-hematological-cancer-care-with-clinical-and-translational-data-presentations-at-ebmt-congress-2024/ 2024-05-30T20:03:18+00:00 https://lakefrontbio.com/press-releases/galapagos-toont-innovatieve-aanpak-in-hematologische-kankerzorg-met-presentaties-over-klinische-en-translationele-data-op-ebmt-congres-2024/ 2024-05-30T20:03:18+00:00 https://lakefrontbio.com/press-releases/galapagos-shareholders-adopt-all-resolutions-proposed-by-the-board-of-directors-at-the-annual-and-extraordinary-shareholders-meetings-2024/ 2024-06-14T20:03:13+00:00 https://lakefrontbio.com/press-releases/galapagos-aandeelhouders-keuren-alle-door-de-raad-van-bestuur-voorgestelde-besluiten-goed-op-de-jaarlijkse-gewone-en-buitengewone-algemene-aandeelhoudersvergaderingen-2024/ 2024-06-14T20:03:14+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-first-quarter-2024-financial-results/ 2024-08-01T20:02:49+00:00 https://lakefrontbio.com/press-releases/galapagos-rapporteert-financiele-resultaten-voor-het-eerste-kwartaal-2024/ 2024-08-01T20:02:49+00:00 https://lakefrontbio.com/press-releases/galapagos-and-blood-centers-of-america-announce-strategic-collaboration-to-accelerate-galapagos-decentralized-car-t-manufacturing-network-in-the-u-s/ 2024-08-20T20:02:08+00:00 https://lakefrontbio.com/press-releases/galapagos-en-blood-centers-of-america-kondigen-een-strategische-samenwerking-aan-om-galapagos-gedecentraliseerde-car-t-productienetwerk-in-de-vs-versneld-op-te-schalen/ 2024-08-20T20:02:09+00:00 https://lakefrontbio.com/press-releases/galapagos-creates-new-subscription-right-plans-5/ 2024-08-23T05:01:23+00:00 https://lakefrontbio.com/press-releases/galapagos-creeert-nieuwe-inschrijvingsrechtenplannen-5/ 2024-08-23T05:01:23+00:00 https://lakefrontbio.com/press-releases/galapagos-and-adaptimmune-sign-clinical-collaboration-agreement-with-an-option-to-exclusively-license-adaptimmunes-tcr-t-cell-therapy-candidate-uza-cel-in-head-neck-cancer-and-potential-f/ 2024-09-03T20:01:46+00:00 https://lakefrontbio.com/press-releases/galapagos-en-adaptimmune-ondertekenen-klinische-samenwerkingsovereenkomst-met-optie-om-adaptimmunes-tcr-t-celtherapiekandidaat-uza-cel-exclusief-in-te-licentieren-voor-hoofd-halskanker-en-mogeli/ 2024-09-03T20:01:47+00:00 https://lakefrontbio.com/press-releases/galapagos-presents-encouraging-new-data-for-cd19-car-t-candidate-glpg5101-in-non-hodgkin-lymphoma-at-eha-2024/ 2024-09-16T20:02:27+00:00 https://lakefrontbio.com/press-releases/galapagos-presenteert-bemoedigende-nieuwe-resultaten-voor-cd19-car-t-kandidaat-glpg5101-in-non-hodgkin-lymfoom-op-eha-2024/ 2024-09-16T20:02:27+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-half-year-2024-financial-results-and-provides-second-quarter-business-update/ 2024-09-30T20:02:55+00:00 https://lakefrontbio.com/press-releases/galapagos-rapporteert-halfjaarcijfers-2024-en-geeft-een-update-over-de-activiteiten-in-het-tweede-kwartaal/ 2024-09-30T20:02:56+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-transparency-notification-from-fmr-llc-7/ 2024-10-07T05:01:37+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-transparantieverklaring-van-fmr-llc-7/ 2024-10-07T05:01:37+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-fda-clearance-of-ind-application-for-phase-1-2-atalanta-1-study-of-cd19-car-t-glpg5101-in-relapsed-refractory-non-hodgkin-lymphoma/ 2024-10-30T20:02:25+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-fda-goedkeuring-aan-van-ind-aanvraag-voor-fase-1-2-atalanta-1-studie-van-cd19-car-t-glpg5101-in-recidief-refractair-non-hodgkin-lymfoom/ 2024-10-30T20:02:26+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-transparency-notification-from-fmr-llc-8/ 2024-11-05T21:03:08+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-transparantieverklaring-van-fmr-llc-8/ 2024-11-05T21:03:09+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-transparency-notification-from-ecor1-capital-2/ 2024-12-07T17:31:12+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-transparantieverklaring-van-ecor1-capital-2/ 2024-12-07T17:31:12+00:00 https://lakefrontbio.com/press-releases/galapagos-completes-transaction-to-transfer-jyseleca-business-to-alfasigma/ 2024-12-19T20:59:59+00:00 https://lakefrontbio.com/press-releases/galapagos-rondt-transactie-af-om-jyseleca-business-over-te-dragen-aan-alfasigma/ 2024-12-19T21:00:35+00:00 https://lakefrontbio.com/press-releases/galapagos-concludes-strategic-evaluation-and-signs-letter-of-intent-to-transfer-jyseleca-business-to-alfasigma/ 2024-12-19T21:02:18+00:00 https://lakefrontbio.com/press-releases/galapagos-rondt-strategische-oefening-af-en-ondertekent-intentieverklaring-om-jyseleca-activiteiten-over-te-dragen-aan-alfasigma/ 2024-12-19T21:02:52+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-transparency-notification-from-ecor1-capital-3/ 2025-01-07T21:02:17+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-transparantieverklaring-van-ecor1-capital-3/ 2025-01-07T21:02:17+00:00 https://lakefrontbio.com/press-releases/galapagos-welcomes-oleg-nodelman-to-its-board-of-directors-to-support-strategic-growth/ 2025-01-08T06:31:37+00:00 https://lakefrontbio.com/press-releases/galapagos-verwelkomt-oleg-nodelman-in-haar-raad-van-bestuur-om-strategische-groei-te-ondersteunen/ 2025-01-08T06:31:37+00:00 https://lakefrontbio.com/press-releases/galapagos-tekent-overeenkomst-om-jyseleca-business-over-te-dragen-aan-alfasigma/ 2025-01-21T21:25:32+00:00 https://lakefrontbio.com/press-releases/galapagos-signs-agreement-to-transfer-jyseleca-business-to-alfasigma/ 2025-01-21T21:27:20+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-third-quarter-2024-financial-results-and-provides-business-update/ 2025-02-12T21:02:13+00:00 https://lakefrontbio.com/press-releases/galapagos-rapporteert-financiele-resultaten-over-het-derde-kwartaal-van-2024-en-geeft-een-bedrijfsupdate/ 2025-02-12T21:02:14+00:00 https://lakefrontbio.com/press-releases/galapagos-to-present-results-of-pioneering-innovation-in-cancer-cell-therapy-at-ash-2024/ 2025-02-17T21:03:02+00:00 https://lakefrontbio.com/press-releases/galapagos-presenteert-resultaten-van-baanbrekende-innovatie-in-kankerceltherapie-op-ash-2024/ 2025-02-17T21:03:02+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-encouraging-new-results-from-ongoing-phase-1-2-study-of-cd19-car-t-cell-therapy-glpg5101-in-patients-with-relapsed-refractory-non-hodgkin-lymphoma/ 2025-02-24T21:02:35+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-bemoedigende-nieuwe-resultaten-aan-van-de-lopende-fase-1-2-studie-van-de-cd19-car-t-celtherapie-glpg5101-bij-patienten-met-recidief-refractair-non-hodgkin-lymfoom/ 2025-02-24T21:02:36+00:00 https://lakefrontbio.com/press-releases/galapagos-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference/ 2025-03-27T20:02:55+00:00 https://lakefrontbio.com/press-releases/galapagos-presenteert-op-de-43ste-jaarlijkse-j-p-morgan-healthcare-conference/ 2025-03-27T20:02:56+00:00 https://lakefrontbio.com/press-releases/galapagos-to-unlock-shareholder-value-by-declaring-its-intent-to-separate-into-two-publicly-traded-entities/ 2025-04-14T22:02:09+00:00 https://lakefrontbio.com/press-releases/galapagos-wil-aandeelhouderswaarde-ontgrendelen-met-voornemen-tot-splitsing-in-twee-beursgenoteerde-entiteiten/ 2025-04-14T22:02:09+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-full-year-2024-results-and-provides-fourth-quarter-business-update/ 2025-04-21T20:02:10+00:00 https://lakefrontbio.com/press-releases/galapagos-rapporteert-resultaten-over-het-gehele-jaar-2024-en-geeft-een-business-update-over-het-vierde-kwartaal/ 2025-04-21T20:02:10+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-transparency-notification-and-13d-filing-from-tang-capital/ 2025-04-22T22:02:22+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-transparantieverklaring-en-13d-filing-van-tang-capital/ 2025-04-22T22:02:23+00:00 https://lakefrontbio.com/press-releases/galapagos-publishes-2024-annual-report-and-announces-annual-shareholders-meeting/ 2025-05-12T07:01:08+00:00 https://lakefrontbio.com/press-releases/galapagos-publiceert-2024-jaarverslag-en-kondigt-jaarlijkse-gewone-algemene-vergadering-aan/ 2025-05-12T07:01:08+00:00 https://lakefrontbio.com/press-releases/galapagos-to-present-at-upcoming-investor-conferences-2/ 2025-05-12T07:01:09+00:00 https://lakefrontbio.com/press-releases/galapagos-presenteert-op-komende-investeerdersconferenties/ 2025-05-12T07:01:09+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-departure-of-thad-huston-cfo-and-coo-as-of-august-1-2025/ 2025-05-27T20:31:04+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-het-vertrek-van-haar-cfo-en-coo-thad-huston-aan-per-1-augustus-2025/ 2025-05-27T20:31:05+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-executive-leadership-updates/ 2025-06-12T20:01:08+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-wijzigingen-aan-in-uitvoerend-leiderschap/ 2025-06-12T20:01:08+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-first-quarter-2025-financial-results-recent-business-highlights-and-near-term-catalysts/ 2025-06-18T19:56:07+00:00 https://lakefrontbio.com/press-releases/galapagos-rapporteert-resultaten-over-het-eerste-kwartaal-van-2025-recente-hoogtepunten-en-verwachtingen-op-korte-termijn/ 2025-06-18T19:56:07+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-strategic-update-on-proposed-separation-executive-leadership-transition-and-board-changes/ 2025-06-23T05:21:07+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-een-strategische-update-aan-over-de-geplande-splitsing-de-transitie-van-het-uitvoerend-leiderschap-en-wijzigingen-in-de-raad-van-bestuur/ 2025-06-23T05:21:07+00:00 https://lakefrontbio.com/press-releases/galapagos-to-present-new-atalanta-1-car-t-data-at-eha-2025-highlighting-low-toxicity-and-rapid-decentralized-delivery-of-fresh-early-memory-enriched-glpg5101-in-r-r-nhl/ 2025-07-23T20:01:04+00:00 https://lakefrontbio.com/press-releases/galapagos-zal-nieuwe-atalanta-1-car-t-data-presenteren-op-eha-2025-met-lage-toxiciteit-en-snelle-gedecentraliseerde-toediening-van-vers-early-memory-verrijkt-glpg5101-bij-r-r-nhl/ 2025-07-23T20:01:05+00:00 https://lakefrontbio.com/press-releases/galapagos-creates-new-subscription-right-plan-3/ 2025-07-23T20:01:06+00:00 https://lakefrontbio.com/press-releases/galapagos-creeert-nieuw-inschrijvingsrechtenplan-3/ 2025-07-23T20:01:06+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-oral-presentations-at-eha-and-icml-2025-featuring-promising-new-data-from-atalanta-1-study-of-investigational-car-t-candidate-glpg5101/ 2025-07-23T20:01:07+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-mondelinge-presentaties-aan-tijdens-eha-en-icml-2025-met-veelbelovende-nieuwe-resultaten-uit-de-atalanta-1-studie-met-car-t-kandidaat-glpg5101/ 2025-07-23T20:01:08+00:00 https://lakefrontbio.com/press-releases/galapagos-presented-new-data-at-icml-2025-from-cohort-3-of-atalanta-1-in-relapsed-refractory-indolent-nhl-patients-demonstrating-high-complete-response-and-mrd-negativity-rates-with-car-t-candidate-g/ 2025-08-06T05:26:07+00:00 https://lakefrontbio.com/press-releases/galapagos-presenteerde-nieuwe-gegevens-op-icml-2025-van-cohort-3-van-de-atalanta-1-studie-bij-patienten-met-recidief-refractair-indolent-nhl-en-toonde-hoge-complete-respons-en-mrd-negativiteitsperce/ 2025-08-06T05:26:08+00:00 https://lakefrontbio.com/press-releases/galapagos-appoints-aaron-cox-as-chief-financial-officer/ 2025-08-07T20:01:18+00:00 https://lakefrontbio.com/press-releases/galapagos-benoemt-aaron-cox-als-chief-financial-officer/ 2025-08-07T20:01:19+00:00 https://lakefrontbio.com/press-releases/galapagos-versterkt-managementteam-met-ervaren-life-sciences-leidinggevenden-om-bedrijfstransformatie-te-versnellen/ 2025-08-21T07:01:07+00:00 https://lakefrontbio.com/press-releases/galapagos-welcomes-seasoned-pharmaceutical-executives-dawn-svoronos-and-jane-griffiths-to-its-board-of-directors/ 2025-08-21T07:01:08+00:00 https://lakefrontbio.com/press-releases/galapagos-verwelkomt-ervaren-farmaceutische-leidinggevenden-dawn-svoronos-en-jane-griffiths-in-haar-raad-van-bestuur/ 2025-08-21T07:01:09+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-half-year-2025-financial-results-and-provides-second-quarter-business-update/ 2025-08-21T07:01:09+00:00 https://lakefrontbio.com/press-releases/galapagos-rapporteert-halfjaarcijfers-2025-en-geeft-een-update-over-de-activiteiten-in-het-tweede-kwartaal/ 2025-08-21T07:01:10+00:00 https://lakefrontbio.com/press-releases/galapagos-bolsters-leadership-team-with-seasoned-life-sciences-executives-to-accelerate-business-transformation/ 2025-08-21T12:16:10+00:00 https://lakefrontbio.com/press-releases/galapagos-nv-announces-u-s-fda-regenerative-medicine-advanced-therapy-rmat-designation-granted-to-glpg5101-for-the-treatment-of-relapsed-refractory-mantle-cell-lymphoma/ 2025-10-01T19:56:05+00:00 https://lakefrontbio.com/press-releases/galapagos-nv-kondigt-aan-dat-glpg5101-de-status-van-regenerative-medicine-advanced-therapy-rmat-van-de-fda-krijgt-voor-de-behandeling-van-recidief-refractair-mantelcellymfoom/ 2025-10-01T19:56:06+00:00 https://lakefrontbio.com/press-releases/galapagos-creeert-nieuw-inschrijvingsrechtenplan-4/ 2025-10-16T20:01:25+00:00 https://lakefrontbio.com/press-releases/galapagos-creates-new-subscription-right-plan-4/ 2025-10-16T20:01:25+00:00 https://lakefrontbio.com/press-releases/galapagos-provides-update-on-strategic-alternatives-for-its-cell-therapy-business/ 2025-10-21T05:26:04+00:00 https://lakefrontbio.com/press-releases/galapagos-geeft-update-over-strategische-alternatieven-voor-haar-celtherapieactiviteiten/ 2025-10-21T05:26:04+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-appointment-of-fred-blakeslee-as-general-counsel/ 2025-10-23T20:01:05+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-benoeming-aan-van-fred-blakeslee-als-general-counsel/ 2025-10-23T20:01:05+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-intention-to-wind-down-cell-therapy-business-as-part-of-the-companys-ongoing-transformation/ 2025-10-30T20:01:04+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-intentie-aan-om-celtherapieactiviteiten-af-te-bouwen-als-onderdeel-van-de-voortdurende-transformatie-van-het-bedrijf/ 2025-10-30T20:01:05+00:00 https://lakefrontbio.com/press-releases/galapagos-to-present-in-vitro-data-at-acr-convergence-2025-suggesting-differentiation-of-glpg3667-from-other-tyk2-inhibitors/ 2025-11-03T20:56:05+00:00 https://lakefrontbio.com/press-releases/galapagos-presenteert-in-vitro-gegevens-tijdens-acr-convergence-2025-die-wijzen-op-differentiatie-van-glpg3667-ten-opzichte-van-andere-tyk2-remmers/ 2025-11-03T20:56:05+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-changes-to-its-board-to-accelerate-strategic-focus-on-business-development/ 2025-11-05T21:01:55+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-wijzigingen-aan-in-de-raad-van-bestuur-om-de-strategische-focus-op-business-development-te-versnellen/ 2025-11-05T21:01:55+00:00 https://lakefrontbio.com/press-releases/galapagos-to-present-new-data-from-cell-therapy-program-at-ash-2025/ 2025-11-26T06:26:05+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-nine-months-2025-financial-results-and-provides-business-update/ 2025-12-08T06:26:03+00:00 https://lakefrontbio.com/press-releases/galapagos-rapporteert-financiele-resultaten-over-de-eerste-negen-maanden-van-2025-en-geeft-bedrijfsupdate/ 2025-12-08T06:26:04+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-transparency-notifications-from-bank-of-america/ 2025-12-18T21:01:05+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-transparantieverklaringen-van-bank-of-america/ 2025-12-18T21:01:05+00:00 https://lakefrontbio.com/press-releases/galapagos-presented-new-atalanta-1-cell-therapy-data-in-mcl-at-ash-2025/ 2026-01-05T21:01:06+00:00 https://lakefrontbio.com/press-releases/galapagos-presenteerde-nieuwe-atalanta-1-celtherapiedata-in-mcl-op-ash-2025/ 2026-01-05T21:01:06+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-topline-results-from-two-phase-3-enabling-studies-with-selective-tyk2-inhibitor-glpg3667-in-dermatomyositis-and-systemic-lupus-erythematosus/ 2026-01-07T20:46:04+00:00 https://lakefrontbio.com/press-releases/galapagos-maakt-topline-resultaten-bekend-van-twee-fase-3-enabling-studies-met-selectieve-tyk2-remmer-glpg3667-bij-dermatomyositis-en-systemische-lupus-erythematodes/ 2026-01-07T20:46:05+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-board-decision-to-initiate-wind-down-of-cell-therapy-activities/ 2026-02-16T21:02:26+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-besluit-van-de-raad-van-bestuur-aan-om-de-afbouw-van-de-celtherapieactiviteiten-te-starten/ 2026-02-16T21:02:26+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-transparantieverklaringen-van-bank-of-america-2/ 2026-02-19T20:56:06+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-transparency-notifications-from-bank-of-america-2/ 2026-02-19T20:56:06+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-transparency-notification-from-bank-of-america/ 2026-02-23T21:01:38+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-transparantieverklaring-van-bank-of-america/ 2026-02-23T21:01:39+00:00 https://lakefrontbio.com/press-releases/galapagos-welcomes-dr-paulo-fontoura-to-its-board-of-directors/ 2026-02-24T21:21:03+00:00 https://lakefrontbio.com/press-releases/galapagos-verwelkomt-dr-paulo-fontoura-in-haar-raad-van-bestuur/ 2026-02-24T21:21:03+00:00 https://lakefrontbio.com/press-releases/galapagos-rapporteert-resultaten-over-het-gehele-jaar-2025-en-geeft-een-business-update-over-het-vierde-kwartaal/ 2026-02-24T21:21:03+00:00 https://lakefrontbio.com/press-releases/galapagos-reports-full-year-2025-financial-results-and-provides-fourth-quarter-business-update/ 2026-02-24T21:22:55+00:00 https://lakefrontbio.com/press-releases/galapagos-and-gilead-in-advanced-discussions-to-collaborate-on-advancing-first-in-class-t-cell-engager-program-for-autoimmune-diseases-2/ 2026-03-23T22:25:00+00:00 https://lakefrontbio.com/app/uploads/Galapagos-NV-8.gif https://lakefrontbio.com/press-releases/galapagos-publishes-2025-annual-report-and-announces-annual-and-extraordinary-shareholders-meetings-2/ 2026-03-26T20:01:00+00:00 https://lakefrontbio.com/app/uploads/Galapagos-NV-6.gif https://lakefrontbio.com/press-releases/galapagos-announces-nomination-of-gino-santini-to-its-board-of-directors-2/ 2026-03-26T20:02:00+00:00 https://lakefrontbio.com/app/uploads/Galapagos-NV-4.gif https://lakefrontbio.com/press-releases/galapagos-and-gilead-enter-into-binding-agreement-to-collaborate-on-advancing-first-in-class-t-cell-engager-program-for-autoimmune-diseases-2/ 2026-03-31T05:30:00+00:00 https://lakefrontbio.com/app/uploads/Galapagos-NV-2.gif https://lakefrontbio.com/press-releases/galapagos-zal-nieuwe-gegevens-presenteren-over-celtherapieprogramma-tijdens-ash-2025/ 2026-04-01T08:59:20+00:00 https://lakefrontbio.com/press-releases/galapagos-ontvangt-transparantieverklaring-van-bank-of-america-2/ 2026-04-18T12:37:16+00:00 https://lakefrontbio.com/press-releases/galapagos-receives-transparency-notification-from-bank-of-america-2/ 2026-04-18T12:37:21+00:00 https://lakefrontbio.com/press-releases/galapagos-en-gilead-in-vergevorderde-gesprekken-over-samenwerking-om-een-first-in-class-t-cel-engagerprogramma-voor-auto-immuunziekten-verder-te-ontwikkelen/ 2026-04-18T12:38:33+00:00 https://lakefrontbio.com/press-releases/galapagos-and-gilead-in-advanced-discussions-to-collaborate-on-advancing-first-in-class-t-cell-engager-program-for-autoimmune-diseases/ 2026-04-18T12:38:39+00:00 https://lakefrontbio.com/press-releases/galapagos-publiceert-2025-jaarverslag-en-kondigt-de-gewone-jaarlijkse-en-buitengewone-algemene-vergaderingen-aan/ 2026-04-18T12:38:45+00:00 https://lakefrontbio.com/press-releases/galapagos-publishes-2025-annual-report-and-announces-annual-and-extraordinary-shareholders-meetings/ 2026-04-18T12:38:51+00:00 https://lakefrontbio.com/press-releases/galapagos-kondigt-de-voordracht-aan-van-gino-santini-tot-lid-van-de-raad-van-bestuur/ 2026-04-18T12:38:56+00:00 https://lakefrontbio.com/press-releases/galapagos-announces-nomination-of-gino-santini-to-its-board-of-directors/ 2026-04-18T12:39:02+00:00 https://lakefrontbio.com/press-releases/galapagos-en-gilead-gaan-definitieve-overeenkomst-aan-over-samenwerking-om-een-first-in-class-t-cel-engagerprogramma-voor-auto-immuunziekten-verder-te-ontwikkelen/ 2026-04-18T12:39:09+00:00 https://lakefrontbio.com/press-releases/galapagos-shareholders-adopt-all-resolutions-proposed-by-the-board-of-directors-at-the-annual-and-extraordinary-shareholders-meetings-2026/ 2026-04-28T20:01:00+00:00 https://lakefrontbio.com/app/uploads/Galapagos-NV.gif https://lakefrontbio.com/press-releases/galapagos-reports-first-quarter-2026-financial-results-and-provides-business-update/ 2026-05-06T20:01:00+00:00 https://lakefrontbio.com/app/uploads/Galapagos-NV-10.gif https://lakefrontbio.com/press-releases/galapagos-rapporteert-financiele-resultaten-over-het-eerste-kwartaal-van-2026-en-geeft-bedrijfsupdate/ 2026-05-08T09:59:04+00:00 https://lakefrontbio.com/app/uploads/Galapagos-NV-11.gif https://lakefrontbio.com/press-releases/aandeelhouders-van-galapagos-keuren-alle-door-de-raad-van-bestuur-voorgestelde-besluiten-goed-op-de-gewone-en-buitengewone-algemene-vergaderingen-van-2026/ 2026-05-08T09:59:53+00:00 https://lakefrontbio.com/app/uploads/Galapagos-NV-1.gif https://lakefrontbio.com/press-releases/galapagos-en-gilead-gaan-definitieve-overeenkomst-aan-over-samenwerking-om-een-first-in-class-t-cel-engagerprogramma-voor-auto-immuunziekten-verder-te-ontwikkelen-2/ 2026-05-08T10:00:22+00:00 https://lakefrontbio.com/app/uploads/Galapagos-NV-3.gif https://lakefrontbio.com/press-releases/galapagos-kondigt-de-voordracht-aan-van-gino-santini-tot-lid-van-de-raad-van-bestuur-2/ 2026-05-08T10:00:31+00:00 https://lakefrontbio.com/app/uploads/Galapagos-NV-5.gif https://lakefrontbio.com/press-releases/galapagos-publiceert-2025-jaarverslag-en-kondigt-de-gewone-jaarlijkse-en-buitengewone-algemene-vergaderingen-aan-2/ 2026-05-08T10:00:36+00:00 https://lakefrontbio.com/app/uploads/Galapagos-NV-7.gif https://lakefrontbio.com/press-releases/galapagos-en-gilead-in-vergevorderde-gesprekken-over-samenwerking-om-een-first-in-class-t-cel-engagerprogramma-voor-auto-immuunziekten-verder-te-ontwikkelen-2/ 2026-05-08T10:01:13+00:00 https://lakefrontbio.com/app/uploads/Galapagos-NV-9.gif